US20060204991A1 - Nucleic acid affinity columns - Google Patents
Nucleic acid affinity columns Download PDFInfo
- Publication number
- US20060204991A1 US20060204991A1 US11/360,146 US36014606A US2006204991A1 US 20060204991 A1 US20060204991 A1 US 20060204991A1 US 36014606 A US36014606 A US 36014606A US 2006204991 A1 US2006204991 A1 US 2006204991A1
- Authority
- US
- United States
- Prior art keywords
- nucleic acid
- nucleic acids
- oligonucleotides
- affinity
- template
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00608—DNA chips
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/0061—The surface being organic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00612—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports the surface being inorganic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00614—Delimitation of the attachment areas
- B01J2219/00617—Delimitation of the attachment areas by chemical means
- B01J2219/00619—Delimitation of the attachment areas by chemical means using hydrophilic or hydrophobic regions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00614—Delimitation of the attachment areas
- B01J2219/00621—Delimitation of the attachment areas by physical means, e.g. trenches, raised areas
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00623—Immobilisation or binding
- B01J2219/00626—Covalent
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00623—Immobilisation or binding
- B01J2219/0063—Other, e.g. van der Waals forces, hydrogen bonding
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00632—Introduction of reactive groups to the surface
- B01J2219/00637—Introduction of reactive groups to the surface by coating it with another layer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00639—Making arrays on substantially continuous surfaces the compounds being trapped in or bound to a porous medium
- B01J2219/00641—Making arrays on substantially continuous surfaces the compounds being trapped in or bound to a porous medium the porous medium being continuous, e.g. porous oxide substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00659—Two-dimensional arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00722—Nucleotides
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
Definitions
- the present invention relates generally to matrices for conducting nucleic acid affinity chromatography More specifically, the present invention relates to methods of preparing affinity chromatography matrices that bind a plurality of different preselected nucleic acids
- the matrices for example, can bind to substantially every known nucleic acid message in a sample
- Affinity chromatography has become a valuable tool for separating biological materials from fluid (typically aqueous) media
- biologically active molecules such as small ligands, proteins, nucleic acids, enzymes, etc
- the basic principle of affinity chromatography involves immobilization of a binding moiety (e g, a ligand) to an insoluble support
- a binding moiety e g, a ligand
- the immobilized binding moiety can then be used to selectively adsorb, e g, from a fluid medium, the target component(s) (e g an enzyme) with which the binding moiety specifically interacts thereby forming a binding moiety/target complex Elution of the adsorbed component can then be achieved by any one of a number of procedures which result in disassociation of the complex
- the target component(s) e g an enzyme
- Elution of the adsorbed component can then be achieved by any one of a number of procedures which result in disassociation of the complex
- the process can be used to isolate specific substances such as enzymes, hormones, specific proteins, inhibitors, antigens, antibodies, etc on the basis of the biologic specific interactions with immobilized ligands
- Nucleic acid affinity chromatography is based on the tendency of complementary, single-stranded nucleic acids to form a double-stranded or duplex structure through complementary base pairing
- a nucleic acid (either DNA or RNA) can easily be attached to a solid substrate (matrix) where it acts as an immobilized ligand that interacts with and forms duplexes with complementary nucleic acids present in a solution contacted to the immobilized ligand Unbound components can be washed away from the bound complex to either provide a solution lacking the target molecules bound to the affinity column, or to provide the isolated target molecules themselves
- the nucleic acids captured in a hybrid duplex can be separated and released from the affinity matrix by denaturation either through heat, adjustment of salt concentration, or the use of a destabilizing agent such as formamide, Tween-20, or sodium dodecyl sulfate (SDS)
- Hybridization the formation of duplex structure between two nucleic acid sequences is highly sequence dependent Sequences have the greatest affinity with each other where, for every purine in one sequence (nucleic acid) there exists a corresponding pyrumidine in the other nucleic acid and vice versa This sequence dependency confers extraordinar specificity on hybridization reactions and permits the preparation of affinity columns that are highly selective for particular target nucleic acids
- Affinity columns are typically used either to isolate a single nucleic acid typically by providing a single species of affinity ligand
- affinity columns bearing a single affinity ligand e g oligo dt columns
- affinity columns bearing a single affinity ligand have been used to isolate a multiplicity of nucleic acids where the nucleic acids all share a common sequence (e g a polyA)
- This invention provides pools (solutions) of nucleic acids, and nucleic acid affinity matrices that bear a large number of different nucleic acid affinity ligands allowing the simultaneous selection and blocking or removal of a large number of different preselected nucleic acids from a sample
- This invention additionally provides methods and devices for the preparation of such affinity matrices
- this invention provides a method of making a nucleic acid pool (solution of nucleic acids) comprising a plurality of different nucleic acids
- the method includes first, providing a nucleic acid amplification template array comprising a surface to which are attached at least 20 oligonucleotides having different predetermined (known) nucleic acid sequences, and second, amplifying the multiplicity of oligonucleotides at least about 10 fold to provide the nucleic acid pool
- the oligoncleotides, or subsequences thereof preferably encode “capture probes” which can be incorporated into an affinity matrix
- each different oligonucleotide is localized in a predetermined region of the surface, the density of the oligonucleotides is preferably greater than about 60 different oligonucleotides per 1 cm 2 , and the different oligonucleotides preferably have an identical terminal 3′ nucleic acid subsequence and an identical terminal 5′ nu
- the method can further involve attaching the pool of nucleic acids to a solid support to form a nucleic acid affinity matrix
- the template nucleic acids comprising the amplification template can be synthesized entirely using light-directed polymer synthesis or channel methods Alternatively the template nucleic acids can be synthesized using a combination of methods
- the 3′ segments (subsequences) of the template nucleic acids can be synthesized using standard phosphotriester (e g, phosphoramidite) chemistry
- a middle (unique) portion of the template nucleic acids can then be synthesized using light-directed polymer synthesis or mechanically-directed synthesis methods
- the 5′ segments (subsequences) of the template nucleic acids can be synthesized using phosphotriester chemistry
- the template nucleic acids can be amplified using any nucleic acid amplification method (e g polymerase chain reaction, ligase chain reaction, transcription amplification, etc) In a preferred embodiment, amplification is by PCR
- the template nucleic acids can be released into solution prior to the amplification (e g by cleavage of a linker joining the template nucleic acids to the substrate) thereby allowing the amplification to be performed in solution Alternatively, and in a preferred embodiment, the amplification is performed without releasing the template nucleic acids from the substrate
- the amplification templates include primer binding regions (e g 3′ and 5′ subsequences flanking the region encoding the capture probe)
- Preferred amplification templates include identical 3′ and 5′ primers
- the primer binding regions of the amplification template oligonucleotides, and hence the corresponding complementary PCR primers preferably range in length from about 4 to about 30 nucleotides
- the primer binding regions can be identical to each other or can differ in nucleotide sequence and/or in length
- the region of the amplification templates encoding the capture probes ranges in length from about 6 to about 50 nucleotides Where it is desired to remove the primer binding regions, they can include a recognition site of a nuclease to facilitate cleavage
- the thermal melting points of the template nucleic acid sequences encoding the capture probes with their complementary sequences varies by less than about 20° C.
- this invention provides for nucleic acid amplification template arrays for practice of the above-described method
- the template arrays comprise a predetermined multiplicity of at least 20 oligonucleotides having different nucleic acid sequences
- Each different oligonucleotide is preferably localized in a predetermined region of said surface
- the density of the oligonucleotides is preferably greater than about 60 different oligonucleotides per 1 cm 2
- the different oligonucleotides have identical terminal 3′ nucleic acid subsequences (e g, primer binding region) and identical terminal 5′ nucleic acid subsequences (e g, primer binding region)
- the 3′ and 5′ subsequences can be identical to each other or differ in length and/or nucleotide sequence
- the subsequences (primer binding regions) of the oligonucleotides, and hence the corresponding complementary PCR primers preferably range in length from about 4
- the region of the template nucleic acids comprising the amplification template array encoding the capture probe preferably ranges in length from about 6 to about 50 nucleotides
- the 3′ and/or 5 ′ subsequences can include a recognition site of a nuclease to facilitate cleavage
- the thermal melting points of the template nucleic acid sequences encoding the capture probes with their complementary sequences varies by less than about 20° C.
- this invention provides an affinity matrix that removes substantially all known nucleic acid messages in a sample and methods of making such an affinity matrix
- the affinity matrix comprises a multiplicity of at least 20 different predetermined oligonucleotides where, for each nucleic acid message, there exists in the affinity matrix an oligonucleotide complementary to the nucleic acid message or a subsequence thereof.
- the matrix does not include every possible oligonucleotide having the same length as the predetermined oligonucleotides
- the oligonucleotides can be selected such that the affinity matrix includes fewer than 80% of the total number of possible nucleotides, preferably fewer than 60% of the total number of possible nucleotides, more preferably fewer than 40% to the total number of possible oligonucleotides, and most preferably less than about 30% or even 20% or even 10% or even 5% of the total possible number of oligonucleotides having the same length as the predetermined oligonucleotides
- Oligonucleotides comprising preferred nucleic acid matrices range in length from about 6 to about 50 nucleotides
- Oligonucleotides for inclusion in such affinity matrices can be selected as described herein by the steps of i) determining an allowable T m interval, ii) determining a mismatch T m threshold, iii) identifying all nucleic acid sequences complementary to a known message whose T m to said message is within the allowable T m interval, iv) determining the likelihood of each of the nucleic acid sequences complementary to the known message also occurring in an unknown message, v) sorting the sequences in order of likelihood with the least likely sequence first to produce a sorted sequence list, vi) selecting the first nucleic acid sequence in the list whose T m to all other known messages in the sample is below the mismatch T m , vi) repeating step vi) until a desired number of nucleic acids that specifically hybridize, under stringent conditions, to the known message are obtained, and viii) repeating steps iii) through vii) until at least one nucleic acid sequence that hybridizes specifically under stringent
- the allowable T m interval ranges from about 30° C. to about 80° C. In another preferred embodiment, the mismatch T m is at least 5° C. lower than the allowable T m interval
- the likelihood can be determined by calculating the probability of occurrence of each of the nucleic acid sequences of step (iii) in a calculated nucleic acid probability distribution
- the oligonucleotides can be produced by amplification from a nucleic acid amplification template array as described above and further herein Further details on the selection of oligonucleotides in the matrix are provided herein.
- this invention provides a nucleic acid affinity matrix that binds to N previously unknown nucleic acid messages and methods of making such nucleic acid matrices
- the method involves the steps of first providing a multiplicity of at least N different predetermined oligonucleotides each oligonucleotide complementary to an unknown nucleic acid message predicted to be present in a nucleic acid sample or complementary to a subsequence of the unknown nucleic acid message, and second, attaching the nucleic acids to a solid support
- the oligonucleotides can be selected by i) providing a list of all possible oligonucleotides of length K, ii) deleting from the list all of the oligonucleotides that hybridize to known nucleic acid messages, iii) calculating a probability of occurrence in a nucleic acid distribution of each of the probes remaining in the list, iv) sorting the list from highest probability to lowest probability, v) selecting the highest probability
- this invention provides a method to enrich a nucleic acid sample for previously unknown expressed RNA sequences
- the method includes the steps of i) providing an affinity matrix having at least one oligonucleotide complementary to each known expressed RNA present in a sample, ii) hybridizing RNA from an undifferentiated control cell and differentiated or activated test cell respectively to the affinity matrix thereby removing known expressed RNAs from the control cell and the differentiated or activated test cell, iii) reverse transcribing the RNA from each of the control cell and the differentiated or activated test cell to produce a cDNA, wherein the reverse transcription adds a polymerase chain reaction prumer binding region to the cDNAs from the differentiated or activated test cell, iv) combining the cDNAs from the differentiated or activated test cell with the cDNA from the control cell such that there is more cDNA from the control cell than cDNA from the differentiated or activated test cell, v) amplifying the mixture
- an “oligonucleotide” refers to a single stranded nucleic acid having a length greater than 2 nucleotides, more preferably greater than about 5 nucleotides, and most preferably greater than about 10, 15, 20, or 50 oligonucleotides
- the oligonucleotides of this invention can range in length up to about 1000 nucleotides, but preferred lengths range up to a maximum of about 500, more preferably up to about 250 nucleotides, and most preferably up to about 150 nucleotides (bases)
- An oligonucleotide can include natural (i e, a, G, C, T or U) or modified bases (i e, 7-deazaguanosine, inosine, etc)
- the bases in an oligonucleotide can be joined by a linkage other than a phosphodiester bond, so long as it does not interfere with hybridization of the oligonucleotide
- nucleic acid “affinity matrix”, as used herein, refers to a solid support or gel to which is attached a multiplicity of different oligonucleotides It is recognized that a nucleic acid template array, itself can act as an affinity matrix However, in a preferred embodiment, where greater loading (binding) capacity is preferred, the affinity matrix is fabricated using nucleic acids amplified from the template array Preferred matrix materials do not interfere with subsequent hybridization of attached oligonucleotides Suitable matrix materials include, but are not limited to paper, glasses, ceramics, metals, metalloids, polacryloylmorpholide, various plastics and plastic copolymers such as NylonTM, TeflonTM, polyethylene, polypropylene, poly(4-methylbutene), polystyrene, polystyrene, polystyrene/latex, polymethacrylate, poly(ethylene terephthalate), rayon, nylon, poly(vinyl butyrate), polyvinylidene difluor
- target nucleic acid refers to a nucleic acid (often denied from a biological sample), to which the oligonucleotide probe is designed to specifically hybridize It is the target nucleic acid(s) that the affinity matrices of this invention are designed to capture (bind)
- the target nucleic acid(s) have sequences that are complementary to the nucleic acid sequence of the oligonucleotide affinity ligand in the affinity matrix
- target nucleic acid may refer to the specific subsequence of a larger nucleic acid to which oligonucleotide is complementary or to the overall sequence (e g, gene, cDNA or mRNA) that it is desired to capture The difference in usage will be apparent from context
- sequence refers to a partial sequence of a longer nucleic acid
- affinity ligand refers to a molecule present in the affinity matrix that specifically binds to, and thereby captures, a target molecule Oligonucleotides are preferred affinity ligands in the affinity matrices of this invention
- nucleic acid template refers to a nucleic acid that acts as a template for a nucleic acid amplification method
- Nucleic acid templates of the present invention serve as templates for the amplification of nucleic acid pools comprising capture probes that are used either in solution or bound to a solid support to provide nucleic acid affinity matrices
- Preferred nucleic acid templates additionally include primer binding regions to facilitate amplification
- a particularly preferred nucleic acid template comprises a unique sequence (subsequence) that encodes the nucleic acid capture probe, flanked on the 5′ and 3′ ends by subsequences that act as primer binding regions
- nucleic acid pool refers to a heterogenous collection of nucleic acids
- a nucleic acid pool can comprises at least 100, 1000, or 10,000 different nucleic acids
- the nucleic acids within a pool often lack an imposed relationship
- a pool can be formed from nucleic acids lacking substantial sequence identity with each other (e g, less than 50% or 75% sequence identity) to each other Sequence identity is determined between optimally aligned sequences by standard algorithms such as GAP, BESTFIT, FASTA, and TFASTA (Wisconsin Genetics Software Package Release 7 0, Genetics Computer Group, 575 Science Dr, Madison, Wis.)
- Nucleic acids within the pool typically range in size from 5-100 bases, preferably, 10-50 bases
- the nucleic acid pools are prepared by amplification of a heterogenous collection of template nucleic acids (e g, as found in a template array)
- blocking reagent when used herein in reference to a nucleic acid pool, refers to a pool or solution of one or more nucleic acids that specifically bind to preselected target sequences The duplexes thus formed are typically incapable of further hybridization
- template array or “amplification template array” refers to a collection of oligonucleotides that acts as a templates for simultaneous amplification of a collection of nucleic acids
- Preferred template arrays are used in the fabrication of affinity ligands for incorporation into an affinity matrix
- nucleic acid or “nucleic acid molecule” refer to a deoxyribonucleotide or ribonucleotide polymer in either single-or double-stranded form, and unless otherwise limited, would encompass known analogs of natural nucleotides that can function in a similar manner as naturally occurring nucleotides
- nucleic acid message refers to a nucleic acid or subsequence thereof that is transcribed when a gene is activated
- nucleic acid messages typically include mRNAs and subsequences thereof.
- nucleic acid messages are used herein to refer to nucleic acids indicative of the presence, absence, or amount of such transcribed sequences
- nucleic acid messages also include nucleic acids derived from such transcripts including, but not limited to cDNA, cRNA, amplification products, and so forth
- hybridizing specifically to refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent conditions when that sequence is present in a complex mixture (e g, total cellular) DNA or RNA
- stringent conditions refers to conditions under which a probe will hybridize to its target subsequence, but to no other sequences Stringent conditions are sequence-dependent and will be different in different circumstances Longer sequences hybridize specifically at higher temperatures Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point (T m ) for the specific sequence (or about 5° C.
- T m is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which half the duplex molecules (i e half the base pairs) are dissociated, or the point where the denaturation rate equals the renaturation rate under given conditions
- stringent conditions will be those in which the salt concentration is less than about 0 01 to 1 0 M Na ton concentration (or other salts) at pH 7 0 to 8 3 and the temperature is at least about 30° C. for short probes (e g, 16 to 50 nucleotides)
- Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide
- capture probe refers to a nucleic acid that is complementary to a target nucleic acid
- the capture probe when incorporated into an affinity matrix acts as an affinity ligand that can specifically hybridize to and thereby capture its respective target nucleic acid It is recognized that capture probes can also exist in solution (e g in nucleic acid pools) where they may act as blocking probes or where they can be subsequently bound to a solid support to produce an affinity matrix
- FIG. 1 illustrates a preferred method of making the affinity matrix of this invention
- a nucleic acid template array bearing a plurality of amplification templates for affinity ligands where each template comprises an affinity ligand (probe) sequence flanked by PCR primer binding sites (primers a* and B*) is synthesized (e g synthesis using light-directed coupling or mechanically-directed coupling)
- the affinity templates are amplified via polymerase chain reaction (PCR) using a biotinylated primer
- resulting biotinylated amplification product is then purified via HPLC (e g Using a mono Q column, Pharmacia, Piscataway, N.J., USA) and then combined with streptavidin coated beads
- HPLC e g Using a mono Q column, Pharmacia, Piscataway, N.J., USA
- This invention provides a method of preparing pools of nucleic acids and, by attaching the pool(s) of nucleic acids to a solid support, a method of preparing nucleic acid affinity matrices
- Both the pool of nucleic acids and the affinity matrices comprise a number of different preselected nucleic acids that act as affinity ligands
- the nucleic acid pools and affinity matrices of this invention bear a large number of different preselected nucleic acid affinity ligands
- the nucleic acid pools and affinity matrices of this invention can thus be used to simultaneously bind to and capture a large number of different nucleic acids and thereby provide a sample with either reduced representation of those nucleic acids or conversely, where the selected nucleic acids are retrieved, a sample enriched for the selected collection of nucleic acids
- Both the amplified pools of nucleic acids and the affinity matrices of this invention have a large number of uses which are discussed below
- a blocking reagent is a reagent that reduces or prevents the hybridization of one or more nucleic acids to particular components of a sample
- a blocking reagent is a reagent that reduces or prevents the hybridization of one or more nucleic acids to particular components of a sample
- a nucleic acid pool contemning nucleic acids complementary to the nucleic acids it is desired to block in the sample can be hybridized to the sample
- the nucleic acid pool (blocking reagent) will hybridize to complementary sequences in the sample, form stable hybrid duplexes, and thereby prevent interaction (e g, nonspecific binding) of the blocked nucleic acids with the capture sequence
- gene products such as actin or GADPH
- nucleic acid pools can be used to provide control nucleic acid mixtures for use as test standards for evaluation and quality control of various nucleic acid detection and/or isolation methods
- Nucleic acid pools can be prepared containing nucleic acids that differ from each other in only one, two, three, or more particular nucleotides The nucleic acid pool can then be used as a standard sample for evaluating the ability of a method (e g a particular HPLC column) to isolate and/or distinguish between the various nucleic acid components of the pool In this way the ability of a device or method to detect, isolate, and/or discriminate particular nucleic acids from a pool of closely related nucleic acids can be evaluated
- affinity matrices of this invention are also useful in a wide variety of contexts For example, where it is desired to analyze mRNA expression levels of particular genes in a complex nucleic acid sample (e g, total mRNA) (see, e g, PCT/US97/01603, filed Jan.
- the affinity matrix can be used to remove a number of preselected gene products (e g, actin, GAPDH, etc) This is accomplished by providing an affinity matrix bearing nucleic acid affinity ligands complementary to the gene products (e g, mRNAs or nucleic acids derived therefrom) or to subsequences thereof.
- Hybridization of the nucleic acid sample to the affinity matrix will result in duplex formation between the affinity ligands and their target nucleic acids Upon elution of the sample from the affinity matrix, the matrix will retain the duplexes nucleic acids leaving a sample depleted of the overexpressed target nucleic acids
- the affinity matrix can also be used to identify unknown mRNAs or cDNAs in a sample
- the affinity matrix contains nucleic acids complementary to every known gene (e g, in a cDNA library, DNA reverse transcribed from an mRNA, mRNA used directly or amplified, or polymerized from a DNA template) in a sample
- capture of the known nucleic acids by the affinity matrix leaves a sample enriched for those nucleic acid sequences that are unknown
- the affinity matrix is used to perform a subtractive hybridization to isolate unknown nucleic acid sequences
- the remaining “unknown” sequences can then be purified and sequenced according to standard methods
- the affinity matrix can also be used to capture (isolate) and thereby purify unknown nucleic acid sequences
- an affinity matrix can be prepared that contains nucleic acid (affinity ligands) that are complementary to sequences not previously identified, or not previously known to be expressed in a particular nucleic acid sample The sample is then hybridized to the affinity matrix and those sequences that are retained on the affinity matrix are “unknown” nucleic acids The retained nucleic acids can be eluted from the matrix (e g at increased temperature, increased destabilizing agent concentration, or decreased salt) and the nucleic acids can then be sequenced according to standard methods
- the affinity matrix can be used to efficiently capture (isolate) a number of known nucleic acid sequences
- the matrix is prepared bearing nucleic acids complementary to those nucleic acids it is desired to isolate
- the sample is contacted to the matrix under conditions where the complementary nucleic acid sequences hybridize to the affinity ligands in the matrix
- the non-hybridized material is washed off the matrix leaving the desired sequences bound
- the hybrid duplexes are then denatured providing a pool of the isolated nucleic acids
- the different nucleic acids in the pool can be subsequently separated according to standard methods (e g gel electrophoresis)
- the affinity matrices can be used to selectively remove nucleic acids from virtually any sample containing nucleic acids (e g, in a cDNA library, DNA reverse transcribed from an mRNA, mRNA used directly or amplified, or polymerized from a DNA template, and so forth)
- the nucleic acids adhering to the column can be removed by washing with a low salt concentration buffer, a buffer containing a destabilizing agent such as formamide, or by elevating the column temperature
- the affinity matrix can be used in a method to enrich a sample for unknown RNA sequences (e g expressed sequence tags (ESTs))
- the method involves, first providing an affinity matrix bearing a library of oligonucleotide probes specific to known RNA (e g, EST) sequences Then, RNA from undifferentiated and/or unactivated cells and RNA from differentiated or activated or pathological (e g, transformed) or otherwise having a different metabolic state are separately hybridized against the affinity matrices to provide two pools of RNAs lacking the known RNA sequences
- RNAs from the differentiated (or activated, etc) cells are reverse transcribed to produce cDNAs bearing cleavable PCR priming regions (See, e g, Van Gelder, et al, Proc Natl Acad Sci USA, 87 1663-1667 (1990) and Eberwine et al Proc Natl Acad Sci USA, 89 3010-3014)
- the RNAs from the undifferentiated cells are reverse transcribed to make cDNAs without PCR priming sites
- the two resulting pools of cDNAs are then combined with the cDNAs from the undifferentiated cells in great excess (e g at least 10 fold excess)
- the cDNAs from the undifferentiated cells will hybridize with complementary sequences from the differentiated cells and form stable duplexes thereby preventing amplification of the corresponding sequences
- those nucleic acids unique to the differentiated cells are differentially amplified
- the PCR effectively performs a subtractive hybrid
- FIG. 1 Methods of preparation of the affinity matrices of this invention are illustrated in FIG. 1
- the methods generally involve first identifying the nucleic acids (capture probes) it is desired to include in the affinity matrix Once the capture probes have been identified, corresponding nucleic acid templates can be designed from which the capture probes can be amplified
- the nucleic acid templates are all attached to a solid support thereby forming a “template array” (see FIG. 1 , “DNA chip”)
- each template nucleic acid is located in a particular preselected region on the solid support
- the DNA chip of FIG. 1 shows an array of “rectangles” where each rectangle contains a different template nucleic acid
- the template nucleic acids are amplified en mass (e g, via PCR) to produce a population of different nucleic acids (see FIG. 1 )
- the number of molecules of each species of nucleic acid in the population will be substantially greater than the number of template molecules used to amplify that species
- the amplified nucleic acids are then attached to a solid support (e g glass or plastic beads) to form an affinity matrix
- a solid support e g glass or plastic beads
- the affinity matrix can be arranged or packaged into a variety of forms
- the matrix material is glass beads having attached capture probes and the beads are packed into a column to thereby produce an affinity column (see FIG. 1 )
- the first step in the claimed method of preparing either a free solution containing a multiplicity of preselected oligonucleotides or an affinity matrix of this invention involves determining which oligonucleotides to include in the solution or matrix Once the desired oligonucleotides are identified, an amplification template for each oligonucleotide is designed and the collection of amplification templates form an amplification template array
- amplification templates can have either the same nucleotide sequence as the desired amplified oligonucleotides or can be complementary to those oligonucleotides
- the sense of the dominant amplified strand can be controlled by using unequal amounts of primer so that the primer for the undesired strand is effectively rate limiting during the amplification step
- Methods of determining appropriate template sense and primer ratios are well known to those of skill in the art (see, e g, PCR Protocols a Guide to Methods and Applications , Innis et al, eds Academic Press, Inc N Y 1990 )
- template sequences capable of amplifying the desired oligonucleotides are discussed as though they have the same sequence as the amplified product, recognizing that the actual corresponding template sequence can be the same or complementary to the ultimate amplified product
- the template nucleic acid can include additional (ancillary) sequences to facilitate amplification and purification of the capture probe
- ancillary sequences to facilitate amplification and purification of the capture probe
- oligonucleotide can be included in the affinity matrix
- oligonucleotides are selected that are complementary to a sequence or subsequence of the nucleic acid(s) it is desired to bind to the affinity matrix
- capture oligonucleotide sequences are selected to minimize self complementary which may result in hairpin formation, or other secondary structure that may interfere with hybridization
- the oligonucleotides can incorporate various base substitutions to reduce secondary structure (e g inosine, 7-deazaguanosine, etc)
- the oligonucleotide affinity ligands are selected to bind and thus remove nucleic acids (e g mRNAs) that are characteristically overexpressed and thus tend to mask the expression of other nucleic acids that are typically expressed at lower levels
- nucleic acids e g mRNAs
- overexpressed nucleic acids include, but are not limited to, the common “housekeeping” genes such as actin, GAPDH, and other well known constitutively expressed genes
- the affinity matrix oligonucleotides are selected to hybridize to one or more target nucleic acids it is desired to purify from a sample of biological molecules
- the affinity matrix is provided containing oligonucleotides complementary to sequences or subsequences of the nucleic acids it is desired to isolate
- the affinity matrix nucleic acids can be selected to bind to, and thus remove, substantially every known mRNA, cDNA, expressed sequence tag (EST), or other known nucleic acid in a sample, and thus provide a nucleic acid sample enriched for unknown sequences
- oligonucleotide “probes” designed for such a selection are chosen to have a relatively uniform melting point (T m )
- T m melting point
- the probes are also preferably selected to have a low probability of hybridizing to an unknown message and thus have a T m above a characteristic threshold which is the melting point of the most similar non-selected nucleic acids expected to be in the sample
- a probe selection process embodying the above-identified criteria can be formalized in the following steps
- the allowable T m interval typically spans a maximum range of about 30° C., preferably a maximum range of about 20° C., more preferably a maximum range of about 10° C. and most preferably a maximum range of about 5° C. Allowable T m intervals range from about 30° C. to about 80° C., more preferably from about 35° C. to about 70° C., more preferably from about 40° C. to about 60° C., and most preferably about 45° C. to about 55° C. As indicated above, the mismatch T m is lower than the low side of the allowable T m interval, typically at least about 5° C. lower, preferably at least about 10° C. lower, more preferably at least about 15° C. lower and most preferably at least about 20° C. lower than the allowable T m interval
- the oligonucleotides can have a preselected length ranging from 2 up to about 1000 nucleotides, more preferably from about 6 to about 150 nucleotides, most preferably from about 6 to about 50 nucleotides
- T m thermal melting points
- the likelihood of an oligonucleotide probe being present in an unknown message is determined by calculating a nucleic acid probability distribution for the particular genome(s) or nucleic acid collection(s) of interest The probability (likelihood) of occurrence of the oligonucleotide probe in that distribution is then determined
- a simple distribution representing the human genome is the frequency of occurrence of each of the bases, a, C, G and T in the human genome Since the human genome is not yet fully sequenced, the complete frequency distribution can be estimated by extrapolation from a sample distribution
- the base composition of the human genome can be estimated by selecting all of the human genome sequences listed in GenBank The total number of each nucleotide a, G, C, and T given as N A , N C , N G , and N T , respectively can then be easily totaled
- the likelihood of an oligonucleotide O of length Y where the oligonucleotide is represented as O X 1 ⁇ X 2 ⁇ X 3 ⁇ X y where X 1 is the nucleotide at position 1, X
- XA) is the probability of occurrence of the dinucleotide AA given a preceding a, and N AA , N GA , N CA and N TA are the numbers of occurrence of the dinucleotides AA, GA, CA and TA, respectively Similarly, the probability of occurrence of the dinucleotide AT given a preceding C is calculated as p ⁇ ( AT ⁇ ⁇ ⁇ XC ) N AT N AC + N GC + N CC + N TC where N AC , N GC , N CC and N TC are the numbers of occurrence of the dinucleotides AC, GC, CC and TC, respectively Other dinucleotide probabilities can be determined in the same manner
- the likelihood of an oligonucleotide occurring in the distribution is then calculated as the product of the marginal probability (frequency of occurrence) of its respective dinucleotides given the preceding base
- O ACGTTACC
- the selection of the particular oligonucleotide frequency distribution used to calculate probe likelihoods is essentially arbitrary As indicated above, to a certain extent, higher order distributions capture more sequence information
- the ability of a particular order probability distribution to accurately reflect likelihood of occurrence of an oligonucleotide mia nucleic acid sample can be determined by comparing predicted likelihood values for various oligonucleotides with the actual frequency of occurrence of those oligonucleotides in a sample nucleic acid data set The closer the predicted likelihood approximates the actual likelihood, the better is the probability distribution
- Such a comparison can be made, for example, by dividing a collection of sequences (e g the GenBank listing of human cDNAs) in half and using the first half to calculate a nucleic acid frequency distribution and predict the likelihood of occurrence of particular oligonucleotides in the second half of the collection The predicted values can then be compared with the actual frequency of occurrence of the oligonucleotides in the second half of the sequence set and the accuracy of the prediction determined
- sequences e g the GenBank listing of human cDNAs
- the method described above provides a means of selecting probes expected to bind to substantially all known sequences in a given nucleic acid sample Conversely, it is possible to select oligonucleotide probes expected to bind to N unknown nucleic acids in a sample, where N is the number of oligonucleotide probes to be selected
- the selection method basically involves creating a list of all possible probes of a given length, deleting from the list probes that hybridize to known messages, and then selecting the N number of probes that have the greatest likelihood of occurring in an unknown message
- the method can be formalized as follows
- Step (4) can additionally include recalculating the probabilities on the condition that the probability distribution contains no nucleic acids complementary to those oligonucleotides already selected
- the list of all possible probes of length K can be calculated in a simple combinatorial manner
- 16 probes of length 2 (AA, AC, AG, AT, CA, CC, TA, TC, TG, TI) and so forth
- the distribution of message sequences can be calculated as described above as can the likelihood of occurrence of each probe in L, occurring in the distribution
- k most preferably ranges from about 6 to about 50 nucleotides
- thermal melting point can also be imposed on selected probes Thus, only probes having a T m above a critical threshold and/or probes having a T m within a specific allowable interval can be selected for inclusion in the affinity matrix
- Either of the above-described probe selection methods can include the additional condition that the T m of and by one of the selected probes to the other selected probes must be below the mismatch T m This will prevent cross hybridization between probes comprising the affinity matrix
- nucleic acid samples e g sequences selected from a genetic database such as GenBank
- nucleic acid frequency distribution of a “population” e g the entire genome of a particular species
- the template nucleic acids forming the template array are used as templates for a nucleic acid amplification step (step 3 of the method described above)
- the nucleic acid template(s) can additionally include ancillary sequences that facilitate amplification and/or purification
- polymerase based amplification systems typically require a double-stranded priming region for binding and initiation of the polymerase
- the double stranded priming region is typically provided by including, in the amplification reaction mixture, primers that are complementary to a portion of the template that is to be amplified
- the prunes bind to the template (at primer binding regions which are complementary to the primers) forming a double stranded region in to which the polymerase binds and initiates transcription
- the template nucleic acids additionally include terminal subsequences (primer binding sequences) that are common to all of the template nucleic acids All of the constituent nucleic acids can then be amplified with a single set of primers and one set of reaction conditions
- particularly preferred template nucleic acids comprise, in order, a common first priming domain, a “unique” domain that encodes the affinity ligand (capture probe), and a second common pruning domain (illustrated in FIG. 1 , as Primer a* binding region, specific affinity ligand, and Primer B* binding region, respectively)
- the first and second priming domains can be identical thereby allowing the use of a single primer, or alternatively, the pruning domains may have different sequences and thus require two primers for amplification
- Priming domains can range in length from about 4 to about 50 nucleic acids, preferably from about 4 to about 40 nucleic acids, more preferably from about 4 to about 30 nucleic acids, and most preferably from about 4 to about 20 nucleic acids
- Particularly preferred priming domains can range from about 6 to about 15 or about 20 nucleic acids in length
- Priming domains are preferably selected so that the priming domain does not also form a subsequence in any of the unique regions of the templates
- the primer domain can additionally corporate a nucleic acid sequence that is recognized by a restriction endonuclease
- a six nucleotide priming sequence can include a four base recognition site which when cleaved by a four base cutter leaves a two base tail Longer nucleotide priming sequences can provide longer recognition sites (e g 5, 6, 7, 10)
- offset sites can be used allowing a clean cut end Recognition sites and restriction endonucleases are well known to those of skill in the art and selection of particular recognition domains and their corresponding restriction enzyme are well known to those of skill in the art (See, e g Gibco BRL, Grand Island, N.Y., USA, or New England Biolabs, Beverly, Mass., USA for a list of restriction nucleases and their recognition sites)
- nucleic acid template array it will be desirable to purify one or more of the nucleic acids amplified from the nucleic acid template array
- purification can be facilitated by incorporating specific (predetermined) nucleic acid “recognition” sequences into the nucleic acid template(s) of the nucleic acid sequences it is desired to purify
- These nucleic acids can then be isolated from the pool of amplified nucleic acids by use of a nucleic acid affinity column with capture probes complementary to the recognition sequences
- a the template(s) can include a poly a tail which will facilitate purification of the amplification product using an oligo dt column
- Other recognition sequences are, of course, suitable as well Generally a recognition sequence will be selected such that it exists only in the amplified nucleic acids it is desired to purify
- the amplification template arrays of this invention are high density oligonucleotide arrays comprising at least about 50, generally at least about 100, more generally at least about 500, most generally at least about 1000, preferably at least about 5,000, more preferably at least about 10,000, most preferably at least about 50,000, 100,000, 500,000 or even at least about 1,000,000 different nucleic acid probes
- Such high density arrays comprise a probe density of generally greater than about 60, more generally greater than about 100, most generally greater than about 600, often greater than about 1000, more often greater than about 5,000, most often greater than about 10,000, preferably greater than about 40,000 more preferably greater than about 100,000, and most preferably greater than about 400,000 different oligonucleotide probes per cm 2
- the array may be fabricated on a surface of virtually any shape or even a multiplicity of surfaces Methods of making such amplification template arrays are discussed below
- the nucleic acids acting as “capture” probes in the affinity matrices of this invention are preferably amplified from a multiplicity of amplification templates, more preferably from a group of templates that comprising a high density array of oligonucleotides
- a multiplicity of amplification templates more preferably from a group of templates that comprising a high density array of oligonucleotides
- Methods of forming high density arrays of oligonucleotides, peptides and other polymer sequences with a minimal number of synthetic steps are known
- the oligonucleotide analogue array can be synthesized on a solid substrate by a variety of methods, including, but not limited to, light-directed chemical coupling, and mechanically directed coupling See Pirrung et al, U.S. Pat. No.
- a glass surface is derivatized with a silane reagent containing a functional group, e g, a hydroxyl or amine group blocked by a photolabile protecting group
- a functional group e g, a hydroxyl or amine group blocked by a photolabile protecting group
- Photolysis through a photolithogaphic mask is used selectively to expose functional groups which are then ready to react with incoming 5′-photoprotected nucleoside phosphoramidites
- the phosphoramidites react only with those sites which are illuminated (and thus exposed by removal of the photolabile blocking group)
- the phosphoramidites only add to those areas selectively exposed from the preceding step
- Peptide nucleic acids are commercially available from, e g, Biosearch, Inc (Bedford, Mass.) which comprise a polyamide backbone and the bases found in naturally occurring nucleosides Peptide nucleic acids are capable of binding to nucleic acids with high specificity, and are considered “oligonucleotide analogues” for purposes of this disclosure
- a typical “flow channel” method applied to the compounds and libraries of the present invention can generally be described as follows Diverse polymer sequences are synthesized at selected regions of a substrate or solid support by forming flow channels on a surface of the substrate through which appropriate reagents flow or in which appropriate reagents are placed
- a monomer “a” is to be bound to the substrate in a first group of selected regions
- all or part of the surface of the substrate in all or a part of the selected regions is activated for binding by, for example, flowing appropriate reagents through all or some of the channels, or by washing the entire substrate with appropriate reagents
- a reagent having the monomer a flows through or is placed in all or some of the channel(s)
- the channels provide fluid contact to the first selected regions, thereby binding the monomer a on the substrate directly or indirectly (via a spacer) in the first selected regions
- a monomer B is coupled to second selected regions, some of which may be included among the first selected regions
- the second selected regions will be in fluid contact with a second flow channel(s) through translation, rotation, or replacement of the channel block on the surface of the substrate, through opening or closing a selected valve, or through deposition of a layer of chemical or photoresist
- a step is performed for activating at least the second regions
- the monomer B is flowed through or placed in the second flow channel(s), binding monomer B at the second selected locations
- the resulting sequences bound to the substrate at this stage of processing will be, for example, a, B, and AB
- the process is repeated to form a vast array of sequences of desired length at known locations on the substrate
- monomer a can be flowed through some of the channels, monomer B can be flowed through other channels, a monomer C can be flowed through still other channels, etc
- monomer a can be flowed through some of the channels, monomer B can be flowed through other channels, a monomer C can be flowed through still other channels, etc
- a protective coating such as a hydrophilic or hydrophobic coating (depending upon the nature of the solvent) is utilized over portions of the substrate to be protected, sometimes in combination with materials that facilitate wetting by the reactant solution in other regions In this manner, the flowing solutions are further prevented from passing outside of their designated flow paths
- a monomer a can be delivered to and coupled with a first group of reaction regions which have been appropriately activated Thereafter, a monomer B can be delivered to and reacted with a second group of activated reaction regions Unlike the flow channel embodiments described above, reactants are delivered by directly depositing (rather than flowing) relatively small quantities of them in selected regions In some steps, of course, the entire substrate surface can be sprayed or otherwise coated with a solution
- a dispenser moves from region to region, depositing only as much monomer as necessary at each stop
- Typical dispensers include a micropipette to deliver the monomer solution to the substrate and a robotic system to control the position of the micropipette with respect to the substrate
- the dispenser includes a series of tubes, a manifold, an array of pipettes, or the like so that various reagents can be delivered to the reaction regions simultaneously
- the high density amplification template arrays can be produced using combined (hybrid) synthesis methods Combined methods utilize standard (e g DMT protected phosphoramidite chemistry) for synthesis of the common regions of the templates and light-directed or mechanically-directed methods for the specific binding (affinity ligand) regions of the templates
- the first primer binding regions can be synthesized on the solid support according to any standard oligonucleotide synthesis method (e g standard phosphotriester chemistry)
- the final base added can bear a MenPoc or an Fmoc protecting group allowing the “unique” (affinity ligand) region to be synthesized as described above using any of the light-directed or mechanically-directed coupling methods
- the last nucleotide added to the “unique” region can be synthesized using any of the light-directed or mechanically-directed coupling methods.
- oligonucleotide synthesis is preferably carried in solid phase using the solid phase phosphoramidite triester method described by Beaucage et al, Tetrahedron Leas 22 (20) 1859-1862 (1981)
- the synthesis can be performed manually or using an automated oligonucleotide synthesizer (see, e g Needham-VanDevanter et al Nucleic Acids Res 12 6159-6168 (1984))
- Methods of oligonucleotide synthesis are routine and well known to those of skill in the art (See, e g Itakura, U.S.
- the 5′ hydroxyl group is preferably protected with a dimethoxytrityl (DMT) group
- DMT dimethoxytrityl
- the last nucleotide coupled however, is preferably protected with a protecting group compatible with the light-directed or mechanically-directed synthesis methods (e g a Fmoc, Tboc, or MenPoc) with a MenPoc group being most preferred for compatibility with light-directed coupling methods.
- a protecting group compatible with the light-directed or mechanically-directed synthesis methods e g a Fmoc, Tboc, or MenPoc
- MenPoc group being most preferred for compatibility with light-directed coupling methods
- the last nucleotide of the unique region added using light-directed synthesis methods will be protected with a DMT group (or other group compatible with the new synthesis chemistry) thereby facilitating synthesis of the second primer binding region using phosphotriester chemistry again
- the common primer binding regions of the template oligonucleotides can be synthesized de novo as described above using the light-directed, mechanically directed or hybrid synthesis methods Alternatively, the complete primer binding regions can be synthesized in a batch process and the completed primer binding region sequence can then be coupled to the solid support forming the amplification template array or to the unique (affinity ligand) region of the templates present in the template array Synthesis according to this approach thus involves coupling the first primer binding region to the substrate of the amplification template array (either directly or through a linker) The primer binding region can be provided with a terminal protecting group, or one can be added afterwards The unique region is then synthesized using light-directed or mechanically-directed coupling methods Finally the second complete primer binding region is covalently linked to the terminus of the unique region Coupling of oligonucleotides simply involves linking the 3′ hydroxyl of one oligonucleotide with the 5′ hydroxyl of a second oligonucleotide (or to an activated
- oligonucleotide synthesis commences by coupling of a nucleotide to a reactive group on a linker which in turn is bound to the solid support
- the reactive group can be a terminal hydroxyl directly on the solid support, or the 3′ or 5 ′ hydroxyl of a nucleotide which in turn is bound to the solid support either directly or through a linker
- Suitable linkers are well known to those of skill in the art (see, e g Gait, et al ed Oligonucleotide Synthesis a Practical Approach , IRL Press, Washington D.C.
- the linkers can be cleaved according to standard methods (e g treatment with concentrated ammonia) Conversely, where the subsequent amplifications are to be performed with the template nucleic acids attached to a solid support, the linker is not cleaved before amplification In a preferred embodiment, the amplification is performed with the template oligonucleotides retained on the solid support The amplification template array can then be reused as a template for a number of amplifications and the production of a large number of affinity matrixes
- the affinity matrices of this invention comprise at least about 50, preferably at least about 100, more preferably at least about 500, 1000, 5,000, 10,000, 50,000, 100,000, 500,000 and even at least about 1,000,000 different nucleic acid probes
- One of skill in the art will appreciate that the chemical synthesis of each nucleic acid individually in quantities sufficient to provide an affinity matrix with sufficient loading capacity to isolate useful quantities of target nucleic acids, is an expensive and time-consuming task
- the nucleic acid probes are obtained by amplification of the template nucleic acids in the above-described template array
- the template pool includes at least one nucleic acid that provides the amplification template for each of the nucleic acid sequences that are to be included in the nucleic acid affinity matrix
- template arrays can include least about 50, preferably at least about 100, more preferably at least about 500, 1000, 5,000, 10,000, 50,000, 100,000, 500,000 and even at least about 1,000,000 different nucleic acid templates
- the nucleic acids can be amplified by any of the amplification methods well known in the art, which include, but are not limited to polymerase chain reaction (PCR) (Innis, et al, PCR Protocols a guide to Methods and Application Academic Press, Inc San Diego, (1990)), ligase chain reaction (LCR) (see Wu and Wallace, Genomics, 4 560 (1989), Landegren, et al, Science, 241 1077 (1988) and Barringer, et al, Gene, 89 117 (1990)), transcription amplification (see Kwoh, et al, Proc Natl Acad Sci ( USA ), 86 1173 (1989)), and self-sustained sequence replication (see Guatelli, et al, Proc Nat Acad Sci ( USA ), 87 1874(1990))
- PCR polymerase chain reaction
- LCR ligase chain reaction
- Amplification of the nucleic acids comprising the template pool can be performed in solution or with the template nucleic acids anchored to a solid support (e g, a glass slide) and thereby forming a template array
- amplification is by polymerase chain reaction (PCR)
- PCR amplification methods are well known to those of skill in the art Basic amplification conditions can be found in a wide variety of references such as PCR Protocols a Guide to Methods and Applications, Innis et al, eds Academic Press, Inc New York (1990)
- amplification can be optimized for particular primer/template array combinations Optimization typically involves adjusting magnesium ion concentration, buffer composition (e g KCl and NaCl ion concentration and buffer pH), and the temperature and length of time allowed for primer annealing, extension and denaturation Methods of optimizing amplification protocols are routine and well known to those of skill in the art (see, e g Chapter 1 in PCR Protocols a Guide to Methods and Applications , Innis et al, eds Academic Press, Inc New York (1990)) In a standard and suitable PCR protocol, the reaction mix includes about 20 pmol of each primer (T m >55° C.
- the amplification is typically run through enough cycles to provide the desired amount of amplified product (capture probe)
- the amplification will be cycled enough to produce at least a 2 fold, generally at least a 5 fold, more generally at least a 10 fold, preferably at least a 100 fold, more preferably at least a 1000 fold, and most preferably at least a 10,000 fold amplification
- the matrix will thus contain at least a 2 fold, generally at least a 5 fold, more generally at least a 10 fold, preferably at least a 100 fold, more preferably at least a 1000 fold, and most preferably at least a 10,000 fold more nucleic acid molecules of each species than the original nucleic acid template array
- a standard amplification will involve 20 to 40 cycles, more preferably about 25 to 35 cycles In a preferred embodiment cycling is carried out for about 25 to about 35 cycles using the following temperature profile Denaturation about 96° C., 15 seconds (a longer initial time is usually desirable), Primer annealing, about 55° C., 30 seconds, and Primer Extension about 72° C., 1 5 minutes Cycling preferably concludes with a final extension at about 72° C. for 5 minutes Reactions can be stopped by chilling to 4° C. and/or by addition of EDTA to 10 mM
- the amplified nucleic acid pool can be used directly, in a preferred embodiment, the amplified nucleic acids are purified away from reaction components (e g incomplete amplification products, nucleotide triphosphates, etc)
- reaction components e g incomplete amplification products, nucleotide triphosphates, etc
- Means of purifying nucleic acid amplification products are well known to those of skill in the art Typically the amplification products are the largest nucleic acids in the reaction mixture and purification techniques based on molecule size are highly effective Such methods include, but are not limited to gel electrophoresis, high performance liquid chromatography (HPLC), affinity chromatography (e g using an affinity column complementary to the primer binding region), capillary electrophoresis, density gradient centrifugation, and the like Particularly preferred is HPLC using an anion exchange column (e g mono Q from Pharmacia, Piscataway, N.J.)
- the amplified nucleic acids include restriction sites (e g, for removal of the primer regions) and the amplified nucleic acids are to be cleaved at the reaction sites before use the cleavage reaction can be performed before or after purification
- it is desirable to cleave the amplification products prior to purification so that the desired cleaved product (e g, capture probes) are purified away from the undesired sequences (e g, primer binding regions) in the single purification step described above
- the amplification product is combined with the restriction endonuclease specific for the cleavage site under conditions (e g, temperature, pH) where the restriction endonuclease is active Suitable reaction conditions for each particular restriction endonuclease are provided by the supplier or manufacturer
- the affinity matrices of this invention can be formulated with virtually any solid material or gel that does not substantially interfere with hybridization of the oligonucleotides
- Suitable matrix materials include paper, glasses, ceramics, metals, metalloids, polacryloylmorpholide, various plastics and plastic copolymers such as NylonTM, TeflonTM, polyethylene, polypropylene, poly(4-methylbutene), polystyrene, polystyrene, polystyrene/latex, polymethacrylate, poly(ethylene terephthalate), rayon, nylon, poly(vinyl butyrate), polyvinylidene difluoride (PVDF), silicones, polyformaldehyde, cellulose, cellulose acetate, nitrocellulose, and the like
- Materials that typically bind nucleic acids e g cellulose
- an affinity matrix composed of such materials is preferably prehybridized with a blocking nucleic acid (e g g cellulose) is
- the affinity matrix can be loaded with virtually any amount of oligonucleotide affinity ligand, the loading being only limited by available binding sites for attachment of the ligand and thus, only limited by the available amount of solid or gel support
- the affinity matrix can take any form that is convenient including beads, porous beads, crushed particles, membranes, tubing, planar surfaces, etc
- Preferred matrix materials are particulate (e g beads) thereby providing increased surface area for attachment of affinity ligands
- Particularly preferred matrix materials can be porous (fenestrated) highly convoluted and/or rugose (e g controlled pore glass, folded membranes, etc)
- the primers used in the amplification can be provided with a conjugated biotin or streptavidin
- the amplified nucleic acids will then bear the biotin or streptavidin and can be coupled to a solid support bearing avidin (streptavidin) or biotin respectively
- the nucleic acid can be covalently coupled to the solid support either directly via an activated group (e g a hydroxyl, a carboxyl) or through a linker that provides reactive moieties that bind to the oligonucleotide and to the matrix material respectively
- Linkers suitable for attaching nucleic acids to matrix materials are also well known Generally linkers are either hetero- or homo-bifunctional molecules that contain two or more reactive sites that may each form a covalent bond with the respective binding partner (the matrix material or the nucleic acid)
- the probe oligonucleotides may be joined by a peptide linker, by a straight or branched chain carbon chan linker, or by a heterocyclic carbon Heterobifunctional cross linking reagents such as active esters of N-ethylmaleimide have been widely used See, for example, Lerner et al Proc Nat Acad Sci ( USA ), 78 3403-3407 (1981) and Kitagawa et al J Bio
- any material to which the oligonucleotide can be bound and which is resistant to nucleic acid hybridization reagents e g Tris-HCl, SSC, etc
- temperatures e g 30° C. to 80° C.
- Particularly preferred matrix materials include glass beads, controlled pore glass, and various polymeric resins such as polystyrene, polystyrene/latex, and the like
- the amplified nucleic acids are purified away from the other components of the amplification mixture (e g triphosphates, truncated amplification products, etc) prior to attachment to the matrix material.
- the other components of the amplification mixture e g triphosphates, truncated amplification products, etc.
- the affinity matrices of this invention rely on hybridization between the nucleic acids comprising the affinity matrix and any target nucleic acids that may be present in the sample to specifically bind to and remove the target nucleic acids from the sample
- Nucleic acid hybridization simply involves contacting the oligonucleotide probes of the affinity matrix and the target nucleic acid under conditions where the probe and its complementary target can form stable hybrid duplexes through complementary base pairing
- the nucleic acids that do not form hybrid duplexes are then washed away leaving the hybridized nucleic acids bound to the affinity matrix
- the duplexes can be denatured (e g by increasing temperature, adding formamide or decreasing salt) and the freed nucleic acids recovered Alternatively the sample contacted with the affinity matrix can be recovered and will be lacking those nucleic acids captured and removed by the affinity matrix
- nucleic acids are denatured by increasing the temperature or decreasing the salt concentration of the buffer containing the nucleic acids
- low stringency conditions e g, low temperature and/or high salt
- hybrid duplexes e g, DNA DNA, RNA RNA, or RNA DNA
- specificity of hybridization is reduced at lower stringency
- higher stringency e g, higher temperature or lower salt
- hybridization conditions may be selected to provide any degree of stringency
- hybridization is performed at low stringency in this case in 6 ⁇ SSPE-T at 37° C. (0 005% Triton X-100) to ensure hybridization and then subsequent washes are performed at higher stringency (e g, 1 ⁇ SSPE-T at 37° C.) to eliminate mismatched hybrid duplexes
- Successive washes may be performed at increasingly higher stringency (e g, down to as low as 0 25 ⁇ SSPE-T at 37° C.
- Hybridization specificity may be evaluated by comparison of hybridization to the sample nucleic acids with hybridization to the various controls that can be present (e g, expression level control such as mRNAs spiked into the sample at known concentrations, etc)
- the wash is performed at the highest stringency that produces consistent results or achieves maximum specific removal of the target nucleic acids from the sample
- duplexes formed between RNAs or DNAs are generally in the order of RNA RNA>RNA DNA>DNA DNA, in solution Long probes have better duplex stability with a target, but poorer mismatch discrimination than shorter probes (mismatch discrimination refers to the measured hybridization signal ratio between a perfect match probe and a single base mismatch probe) Shorter probes (e g, 8-mers) discriminate mismatches very well, but the overall duplex stability is low
- T m thermal stability
- G-C guanine-cytosine
- Altered duplex stability conferred by using oligonucleotide analogue probes can be ascertained by following, e g, fluorescence signal intensity of oligonucleotide analogue arrays hybridized with a target oligonucleotide over time
- the data allow optimization of specific hybridization conditions at, e g, room temperature (for simplified diagnostic applications in the future)
- the affinity matrix is packed into a columnar casing
- the sample is then applied to the affinity matrix (e g injected onto a column or applied to a column by a pump such as a sampling pump driven by an autosampler)
- the affinity matrix (e g affinity column) bearing the sample is subjected to conditions under which the nucleic acid probes comprising the affinity matrix hybridize specifically with complementary target nucleic acids Such conditions are accomplished by maintaining appropriate pH, salt and temperature conditions to facilitate hybridization as discussed above
Abstract
This invention provides nucleic acid affinity matrices that bear a large number of different nucleic acid affinity ligands allowing the simultaneous selection and removal of a large number of preselected nucleic acids from the sample Methods of producing such affinity matrices are also provided In general the methods involve the steps of a) providing a nucleic acid amplification template array comprising a surface to which are attached at least 50 oligonucleotides having different nucleic acid sequences, and wherein each different oligonucleotide is localized in a predetermined region of said surface, the density of said oligonucleotides is greater than about 60 different oligonucleotides per 1 cm2, and all of said different oligonucleotides have an identical terminal 3′ nucleic acid sequence and an identical terminal 5′ nucleic acid sequence b) amplifying said multiplicity of oligonucleotides to provide a pool of amplified nucleic acids, and c) attaching the pool of nucleic acids to a solid support
Description
- The present application derives priority from provisional application U.S. Ser. No. 60/013,231, filed Mar. 11, 1996, which is incorporated by reference in its entirety for all purposes
- The present invention relates generally to matrices for conducting nucleic acid affinity chromatography More specifically, the present invention relates to methods of preparing affinity chromatography matrices that bind a plurality of different preselected nucleic acids The matrices, for example, can bind to substantially every known nucleic acid message in a sample
- Affinity chromatography has become a valuable tool for separating biological materials from fluid (typically aqueous) media Examples include biologically active molecules such as small ligands, proteins, nucleic acids, enzymes, etc
- The basic principle of affinity chromatography involves immobilization of a binding moiety (e g, a ligand) to an insoluble support The immobilized binding moiety can then be used to selectively adsorb, e g, from a fluid medium, the target component(s) (e g an enzyme) with which the binding moiety specifically interacts thereby forming a binding moiety/target complex Elution of the adsorbed component can then be achieved by any one of a number of procedures which result in disassociation of the complex Thus the specific biologic properties of biological macromolecules can be exploited for purification The process can be used to isolate specific substances such as enzymes, hormones, specific proteins, inhibitors, antigens, antibodies, etc on the basis of the biologic specific interactions with immobilized ligands
- Nucleic acid affinity chromatography is based on the tendency of complementary, single-stranded nucleic acids to form a double-stranded or duplex structure through complementary base pairing A nucleic acid (either DNA or RNA) can easily be attached to a solid substrate (matrix) where it acts as an immobilized ligand that interacts with and forms duplexes with complementary nucleic acids present in a solution contacted to the immobilized ligand Unbound components can be washed away from the bound complex to either provide a solution lacking the target molecules bound to the affinity column, or to provide the isolated target molecules themselves The nucleic acids captured in a hybrid duplex can be separated and released from the affinity matrix by denaturation either through heat, adjustment of salt concentration, or the use of a destabilizing agent such as formamide, Tween-20, or sodium dodecyl sulfate (SDS)
- Hybridization (the formation of duplex structure) between two nucleic acid sequences is highly sequence dependent Sequences have the greatest affinity with each other where, for every purine in one sequence (nucleic acid) there exists a corresponding pyrumidine in the other nucleic acid and vice versa This sequence dependency confers exquisite specificity on hybridization reactions and permits the preparation of affinity columns that are highly selective for particular target nucleic acids
- Affinity columns (matrices) are typically used either to isolate a single nucleic acid typically by providing a single species of affinity ligand Alternatively, affinity columns bearing a single affinity ligand (e g oligo dt columns) have been used to isolate a multiplicity of nucleic acids where the nucleic acids all share a common sequence (e g a polyA)
- This invention provides pools (solutions) of nucleic acids, and nucleic acid affinity matrices that bear a large number of different nucleic acid affinity ligands allowing the simultaneous selection and blocking or removal of a large number of different preselected nucleic acids from a sample This invention additionally provides methods and devices for the preparation of such affinity matrices
- In one embodiment, this invention provides a method of making a nucleic acid pool (solution of nucleic acids) comprising a plurality of different nucleic acids The method includes first, providing a nucleic acid amplification template array comprising a surface to which are attached at least 20 oligonucleotides having different predetermined (known) nucleic acid sequences, and second, amplifying the multiplicity of oligonucleotides at least about 10 fold to provide the nucleic acid pool The oligoncleotides, or subsequences thereof, preferably encode “capture probes” which can be incorporated into an affinity matrix In a preferred embodiment, each different oligonucleotide is localized in a predetermined region of the surface, the density of the oligonucleotides is preferably greater than about 60 different oligonucleotides per 1 cm2, and the different oligonucleotides preferably have an
identical terminal 3′ nucleic acid subsequence and anidentical terminal 5′ nucleic acid subsequence The 3′ and 5′ nucleic acid subsequences can be the same as each other or can differ in length and/or nucleotide sequence The 3′ and 5′ subsequences preferably flank “unique” central subsequences encoding the capture probes - The method can further involve attaching the pool of nucleic acids to a solid support to form a nucleic acid affinity matrix The template nucleic acids comprising the amplification template can be synthesized entirely using light-directed polymer synthesis or channel methods Alternatively the template nucleic acids can be synthesized using a combination of methods For example, in one embodiment, the 3′ segments (subsequences) of the template nucleic acids can be synthesized using standard phosphotriester (e g, phosphoramidite) chemistry A middle (unique) portion of the template nucleic acids can then be synthesized using light-directed polymer synthesis or mechanically-directed synthesis methods Finally, the 5′ segments (subsequences) of the template nucleic acids can be synthesized using phosphotriester chemistry
- The template nucleic acids can be amplified using any nucleic acid amplification method (e g polymerase chain reaction, ligase chain reaction, transcription amplification, etc) In a preferred embodiment, amplification is by PCR The template nucleic acids can be released into solution prior to the amplification (e g by cleavage of a linker joining the template nucleic acids to the substrate) thereby allowing the amplification to be performed in solution Alternatively, and in a preferred embodiment, the amplification is performed without releasing the template nucleic acids from the substrate
- In a preferred embodiment, the amplification templates include primer binding regions (
e g 3′ and 5′ subsequences flanking the region encoding the capture probe) Preferred amplification templates include identical 3′ and 5′ primers The primer binding regions of the amplification template oligonucleotides, and hence the corresponding complementary PCR primers, preferably range in length from about 4 to about 30 nucleotides The primer binding regions can be identical to each other or can differ in nucleotide sequence and/or in length - In a particularly preferred embodiment, the region of the amplification templates encoding the capture probes (the non-identical portion of the amplification template(s)) ranges in length from about 6 to about 50 nucleotides Where it is desired to remove the primer binding regions, they can include a recognition site of a nuclease to facilitate cleavage In a particularly preferred embodiment, the thermal melting points of the template nucleic acid sequences encoding the capture probes with their complementary sequences varies by less than about 20° C.
- In another embodiment, this invention provides for nucleic acid amplification template arrays for practice of the above-described method In a preferred embodiment, the template arrays comprise a predetermined multiplicity of at least 20 oligonucleotides having different nucleic acid sequences Each different oligonucleotide is preferably localized in a predetermined region of said surface The density of the oligonucleotides is preferably greater than about 60 different oligonucleotides per 1 cm2, and the different oligonucleotides have
identical terminal 3′ nucleic acid subsequences (e g, primer binding region) andidentical terminal 5′ nucleic acid subsequences (e g, primer binding region) The 3′ and 5′ subsequences can be identical to each other or differ in length and/or nucleotide sequence The subsequences (primer binding regions) of the oligonucleotides, and hence the corresponding complementary PCR primers, preferably range in length from about 4 to about 30 nucleotides - The region of the template nucleic acids comprising the amplification template array encoding the capture probe (the “unique” non-terminal subsequence) preferably ranges in length from about 6 to about 50 nucleotides Where it is desired to remove the primer binding regions, the 3′ and/or 5′ subsequences can include a recognition site of a nuclease to facilitate cleavage In a particularly preferred embodiment, the thermal melting points of the template nucleic acid sequences encoding the capture probes with their complementary sequences varies by less than about 20° C.
- In another embodiment this invention provides an affinity matrix that removes substantially all known nucleic acid messages in a sample and methods of making such an affinity matrix In a preferred embodiment, the affinity matrix comprises a multiplicity of at least 20 different predetermined oligonucleotides where, for each nucleic acid message, there exists in the affinity matrix an oligonucleotide complementary to the nucleic acid message or a subsequence thereof. The matrix, however, does not include every possible oligonucleotide having the same length as the predetermined oligonucleotides The oligonucleotides can be selected such that the affinity matrix includes fewer than 80% of the total number of possible nucleotides, preferably fewer than 60% of the total number of possible nucleotides, more preferably fewer than 40% to the total number of possible oligonucleotides, and most preferably less than about 30% or even 20% or even 10% or even 5% of the total possible number of oligonucleotides having the same length as the predetermined oligonucleotides Oligonucleotides comprising preferred nucleic acid matrices range in length from about 6 to about 50 nucleotides
- Oligonucleotides for inclusion in such affinity matrices can be selected as described herein by the steps of i) determining an allowable Tm interval, ii) determining a mismatch Tm threshold, iii) identifying all nucleic acid sequences complementary to a known message whose Tm to said message is within the allowable Tm interval, iv) determining the likelihood of each of the nucleic acid sequences complementary to the known message also occurring in an unknown message, v) sorting the sequences in order of likelihood with the least likely sequence first to produce a sorted sequence list, vi) selecting the first nucleic acid sequence in the list whose Tm to all other known messages in the sample is below the mismatch Tm, vi) repeating step vi) until a desired number of nucleic acids that specifically hybridize, under stringent conditions, to the known message are obtained, and viii) repeating steps iii) through vii) until at least one nucleic acid sequence that hybridizes specifically under stringent conditions to each known nucleic acid message is selected Step (vi) can further comprise selecting the probe that additionally has a Tm to all already selected nucleic acids below the mismatch Tm
- In one embodiment the allowable Tm interval ranges from about 30° C. to about 80° C. In another preferred embodiment, the mismatch Tm is at least 5° C. lower than the allowable Tm interval The likelihood can be determined by calculating the probability of occurrence of each of the nucleic acid sequences of step (iii) in a calculated nucleic acid probability distribution The oligonucleotides can be produced by amplification from a nucleic acid amplification template array as described above and further herein Further details on the selection of oligonucleotides in the matrix are provided herein.
- In still yet another embodiment, this invention provides a nucleic acid affinity matrix that binds to N previously unknown nucleic acid messages and methods of making such nucleic acid matrices The method involves the steps of first providing a multiplicity of at least N different predetermined oligonucleotides each oligonucleotide complementary to an unknown nucleic acid message predicted to be present in a nucleic acid sample or complementary to a subsequence of the unknown nucleic acid message, and second, attaching the nucleic acids to a solid support The oligonucleotides can be selected by i) providing a list of all possible oligonucleotides of length K, ii) deleting from the list all of the oligonucleotides that hybridize to known nucleic acid messages, iii) calculating a probability of occurrence in a nucleic acid distribution of each of the probes remaining in the list, iv) sorting the list from highest probability to lowest probability, v) selecting the highest probability oligonucleotide for inclusion in the affinity matrix, and vi) repeating steps (iii) through (v) until N oligonucleotides are selected The selection of step (vi) can further comprise recalculating the probability on the condition that probability distribution contains no nucleic acids complementary to those oligonucleotides already selected Selection step (v) can further include selecting an allowable Tm interval and selecting the highest probability oligonucleotide whose Tm lies within the allowable Tm interval The oligonucleotides can be amplified from the nucleic acid amplification template arrays described above In a particularly preferred embodiment, the oligonucleotides are attached to a solid support (e g glass beads) by a covalent linkage to a biotin which is joined to a streptavidin which is covalently joined to the solid support
- Finally, in still yet another embodiment, this invention provides a method to enrich a nucleic acid sample for previously unknown expressed RNA sequences The method includes the steps of i) providing an affinity matrix having at least one oligonucleotide complementary to each known expressed RNA present in a sample, ii) hybridizing RNA from an undifferentiated control cell and differentiated or activated test cell respectively to the affinity matrix thereby removing known expressed RNAs from the control cell and the differentiated or activated test cell, iii) reverse transcribing the RNA from each of the control cell and the differentiated or activated test cell to produce a cDNA, wherein the reverse transcription adds a polymerase chain reaction prumer binding region to the cDNAs from the differentiated or activated test cell, iv) combining the cDNAs from the differentiated or activated test cell with the cDNA from the control cell such that there is more cDNA from the control cell than cDNA from the differentiated or activated test cell, v) amplifying the mixture of cDNAs using primers complementary to the primer binding regions such that the amplification results in an enrichment of nucleic acid sequences transcribed in the differentiated or activated test cell at a significantly higher level than in the control cell In a preferred embodiment, ratio of cDNA from the control cell to cDNA from the test cell, In step (iv) is at least about a 5 l, more preferably at least about 10 l, most preferably at least about 20 l
- Definitions
- As used herein, an “oligonucleotide” refers to a single stranded nucleic acid having a length greater than 2 nucleotides, more preferably greater than about 5 nucleotides, and most preferably greater than about 10, 15, 20, or 50 oligonucleotides The oligonucleotides of this invention can range in length up to about 1000 nucleotides, but preferred lengths range up to a maximum of about 500, more preferably up to about 250 nucleotides, and most preferably up to about 150 nucleotides (bases) An oligonucleotide can include natural (i e, a, G, C, T or U) or modified bases (i e, 7-deazaguanosine, inosine, etc) In addition, the bases in an oligonucleotide can be joined by a linkage other than a phosphodiester bond, so long as it does not interfere with hybridization of the oligonucleotide Thus, oligonucleotides can be peptide nucleic acids in which one or more of the constituent bases are joined by peptide bonds rather than phosphodiester linkages
- The term nucleic acid “affinity matrix”, as used herein, refers to a solid support or gel to which is attached a multiplicity of different oligonucleotides It is recognized that a nucleic acid template array, itself can act as an affinity matrix However, in a preferred embodiment, where greater loading (binding) capacity is preferred, the affinity matrix is fabricated using nucleic acids amplified from the template array Preferred matrix materials do not interfere with subsequent hybridization of attached oligonucleotides Suitable matrix materials include, but are not limited to paper, glasses, ceramics, metals, metalloids, polacryloylmorpholide, various plastics and plastic copolymers such as Nylon™, Teflon™, polyethylene, polypropylene, poly(4-methylbutene), polystyrene, polystyrene, polystyrene/latex, polymethacrylate, poly(ethylene terephthalate), rayon, nylon, poly(vinyl butyrate), polyvinylidene difluoride (PVDF), silicones, polyformaldehyde, cellulose, cellulose acetate, nutrocellulose, and controlled-pore glass (Controlled Pore Glass, Inc, Fairfield, N.J.), aerogels (see, e g, Ruben et al, J Materials Science 27, 4341-4349 (1992), Rao et al, J Maternal Science 28, 3021 (1993), Back et al, J Phys D Appl Phys 22, 730-734 (1989), Kim & Jang, J Am Ceram Soc 74, 1987-92 (1991) and the like, and other materials generally known to be suitable for use in affinity columns (e g HPLC columns)
- The term “target nucleic acid” refers to a nucleic acid (often denied from a biological sample), to which the oligonucleotide probe is designed to specifically hybridize It is the target nucleic acid(s) that the affinity matrices of this invention are designed to capture (bind) The target nucleic acid(s) have sequences that are complementary to the nucleic acid sequence of the oligonucleotide affinity ligand in the affinity matrix The term target nucleic acid may refer to the specific subsequence of a larger nucleic acid to which oligonucleotide is complementary or to the overall sequence (e g, gene, cDNA or mRNA) that it is desired to capture The difference in usage will be apparent from context
- The term “subsequence” refers to a partial sequence of a longer nucleic acid
- The term “affinity ligand” as used herein refers to a molecule present in the affinity matrix that specifically binds to, and thereby captures, a target molecule Oligonucleotides are preferred affinity ligands in the affinity matrices of this invention
- The terms “nucleic acid template” or “template”, as used herein, refer to a nucleic acid that acts as a template for a nucleic acid amplification method Nucleic acid templates of the present invention serve as templates for the amplification of nucleic acid pools comprising capture probes that are used either in solution or bound to a solid support to provide nucleic acid affinity matrices Preferred nucleic acid templates additionally include primer binding regions to facilitate amplification A particularly preferred nucleic acid template comprises a unique sequence (subsequence) that encodes the nucleic acid capture probe, flanked on the 5′ and 3′ ends by subsequences that act as primer binding regions
- The term “nucleic acid pool” as used herein, refers to a heterogenous collection of nucleic acids For example, a nucleic acid pool can comprises at least 100, 1000, or 10,000 different nucleic acids The nucleic acids within a pool often lack an imposed relationship For example, a pool can be formed from nucleic acids lacking substantial sequence identity with each other (e g, less than 50% or 75% sequence identity) to each other Sequence identity is determined between optimally aligned sequences by standard algorithms such as GAP, BESTFIT, FASTA, and TFASTA (Wisconsin Genetics Software Package Release 7 0, Genetics Computer Group, 575 Science Dr, Madison, Wis.) Nucleic acids within the pool typically range in size from 5-100 bases, preferably, 10-50 bases Typically the nucleic acid pools are prepared by amplification of a heterogenous collection of template nucleic acids (e g, as found in a template array)
- The term “blocking reagent”, when used herein in reference to a nucleic acid pool, refers to a pool or solution of one or more nucleic acids that specifically bind to preselected target sequences The duplexes thus formed are typically incapable of further hybridization
- The term “template array” or “amplification template array” refers to a collection of oligonucleotides that acts as a templates for simultaneous amplification of a collection of nucleic acids Preferred template arrays are used in the fabrication of affinity ligands for incorporation into an affinity matrix
- The terms “nucleic acid” or “nucleic acid molecule” refer to a deoxyribonucleotide or ribonucleotide polymer in either single-or double-stranded form, and unless otherwise limited, would encompass known analogs of natural nucleotides that can function in a similar manner as naturally occurring nucleotides
- The phrase “nucleic acid message”, as used herein refers to a nucleic acid or subsequence thereof that is transcribed when a gene is activated Thus, nucleic acid messages typically include mRNAs and subsequences thereof. However, nucleic acid messages are used herein to refer to nucleic acids indicative of the presence, absence, or amount of such transcribed sequences Thus, nucleic acid messages also include nucleic acids derived from such transcripts including, but not limited to cDNA, cRNA, amplification products, and so forth
- The phrase “hybridizing specifically to”, refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent conditions when that sequence is present in a complex mixture (e g, total cellular) DNA or RNA The term “stringent conditions” refers to conditions under which a probe will hybridize to its target subsequence, but to no other sequences Stringent conditions are sequence-dependent and will be different in different circumstances Longer sequences hybridize specifically at higher temperatures Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point (Tm) for the specific sequence (or about 5° C. lower than the sequence with the highest melting point for a group of sequences) at a defined ionic strength and pH The Tm is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which half the duplex molecules (i e half the base pairs) are dissociated, or the point where the denaturation rate equals the renaturation rate under given conditions Typically, stringent conditions will be those in which the salt concentration is less than about 0 01 to 1 0 M Na ton concentration (or other salts) at pH 7 0 to 8 3 and the temperature is at least about 30° C. for short probes (e g, 16 to 50 nucleotides) Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide
- The term “capture probe”, as used herein, refers to a nucleic acid that is complementary to a target nucleic acid The capture probe, when incorporated into an affinity matrix acts as an affinity ligand that can specifically hybridize to and thereby capture its respective target nucleic acid It is recognized that capture probes can also exist in solution (e g in nucleic acid pools) where they may act as blocking probes or where they can be subsequently bound to a solid support to produce an affinity matrix
-
FIG. 1 illustrates a preferred method of making the affinity matrix of this invention Briefly, a nucleic acid template array bearing a plurality of amplification templates for affinity ligands where each template comprises an affinity ligand (probe) sequence flanked by PCR primer binding sites (primers a* and B*) is synthesized (e g synthesis using light-directed coupling or mechanically-directed coupling) The affinity templates are amplified via polymerase chain reaction (PCR) using a biotinylated primer The resulting biotinylated amplification product is then purified via HPLC (e g Using a mono Q column, Pharmacia, Piscataway, N.J., USA) and then combined with streptavidin coated beads The resulting affinity matrix is then packed into a column - I. Amplified Nucleic Acid Pools and Affinity Matrices.
- This invention provides a method of preparing pools of nucleic acids and, by attaching the pool(s) of nucleic acids to a solid support, a method of preparing nucleic acid affinity matrices Both the pool of nucleic acids and the affinity matrices comprise a number of different preselected nucleic acids that act as affinity ligands Unlike affinity columns found in the prior art, the nucleic acid pools and affinity matrices of this invention bear a large number of different preselected nucleic acid affinity ligands The nucleic acid pools and affinity matrices of this invention can thus be used to simultaneously bind to and capture a large number of different nucleic acids and thereby provide a sample with either reduced representation of those nucleic acids or conversely, where the selected nucleic acids are retrieved, a sample enriched for the selected collection of nucleic acids Both the amplified pools of nucleic acids and the affinity matrices of this invention have a large number of uses which are discussed below
- A) Amplified Nucleic Acid Pools.
- The nucleic acid pools of this invention are particularly useful when used as a blocking reagents (blocking probes) A blocking reagent is a reagent that reduces or prevents the hybridization of one or more nucleic acids to particular components of a sample For example, where it is desired to detect a particular (target) nucleic acid that is expressed at low levels in a nucleic acid sample, selective elimination of other nucleic acids that are present at high levels in the sample can improve detection and isolation of the target sequence In this case, a nucleic acid pool contemning nucleic acids complementary to the nucleic acids it is desired to block in the sample can be hybridized to the sample The nucleic acid pool (blocking reagent) will hybridize to complementary sequences in the sample, form stable hybrid duplexes, and thereby prevent interaction (e g, nonspecific binding) of the blocked nucleic acids with the capture sequence Thus, for example, where gene products, such as actin or GADPH, are typically overexpressed in a nucleic acid sample, the nucleic acid pool will be prepared containing nucleic acids complementary to those (e g, actin and GADPH)RNAs When the blocking reagent is combined (hybridized) to the sample, the GADPH and actin RNAs will hybridize with the blocking reagent and their participation in other reactions will be reduced or eliminated
- In another embodiment, the nucleic acid pools can be used to provide control nucleic acid mixtures for use as test standards for evaluation and quality control of various nucleic acid detection and/or isolation methods Nucleic acid pools can be prepared containing nucleic acids that differ from each other in only one, two, three, or more particular nucleotides The nucleic acid pool can then be used as a standard sample for evaluating the ability of a method (e g a particular HPLC column) to isolate and/or distinguish between the various nucleic acid components of the pool In this way the ability of a device or method to detect, isolate, and/or discriminate particular nucleic acids from a pool of closely related nucleic acids can be evaluated
- B) Affinity Matrices.
- The affinity matrices of this invention are also useful in a wide variety of contexts For example, where it is desired to analyze mRNA expression levels of particular genes in a complex nucleic acid sample (e g, total mRNA) (see, e g, PCT/US97/01603, filed Jan. 22, 1997, incorporated by reference in its entirety for all purposes) it is often desirable to eliminate nucleic acids produced by genes that are constitutively overexpressed and thereby tend to mask gene products expressed at characteristically lower levels Thus, in one embodiment, the affinity matrix can be used to remove a number of preselected gene products (e g, actin, GAPDH, etc) This is accomplished by providing an affinity matrix bearing nucleic acid affinity ligands complementary to the gene products (e g, mRNAs or nucleic acids derived therefrom) or to subsequences thereof. Hybridization of the nucleic acid sample to the affinity matrix will result in duplex formation between the affinity ligands and their target nucleic acids Upon elution of the sample from the affinity matrix, the matrix will retain the duplexes nucleic acids leaving a sample depleted of the overexpressed target nucleic acids
- The affinity matrix can also be used to identify unknown mRNAs or cDNAs in a sample Where the affinity matrix contains nucleic acids complementary to every known gene (e g, in a cDNA library, DNA reverse transcribed from an mRNA, mRNA used directly or amplified, or polymerized from a DNA template) in a sample, capture of the known nucleic acids by the affinity matrix leaves a sample enriched for those nucleic acid sequences that are unknown In effect, the affinity matrix is used to perform a subtractive hybridization to isolate unknown nucleic acid sequences The remaining “unknown” sequences can then be purified and sequenced according to standard methods
- The affinity matrix can also be used to capture (isolate) and thereby purify unknown nucleic acid sequences For example, an affinity matrix can be prepared that contains nucleic acid (affinity ligands) that are complementary to sequences not previously identified, or not previously known to be expressed in a particular nucleic acid sample The sample is then hybridized to the affinity matrix and those sequences that are retained on the affinity matrix are “unknown” nucleic acids The retained nucleic acids can be eluted from the matrix (e g at increased temperature, increased destabilizing agent concentration, or decreased salt) and the nucleic acids can then be sequenced according to standard methods
- Similarly, the affinity matrix can be used to efficiently capture (isolate) a number of known nucleic acid sequences Again, the matrix is prepared bearing nucleic acids complementary to those nucleic acids it is desired to isolate The sample is contacted to the matrix under conditions where the complementary nucleic acid sequences hybridize to the affinity ligands in the matrix The non-hybridized material is washed off the matrix leaving the desired sequences bound The hybrid duplexes are then denatured providing a pool of the isolated nucleic acids The different nucleic acids in the pool can be subsequently separated according to standard methods (e g gel electrophoresis)
- As indicated above the affinity matrices can be used to selectively remove nucleic acids from virtually any sample containing nucleic acids (e g, in a cDNA library, DNA reverse transcribed from an mRNA, mRNA used directly or amplified, or polymerized from a DNA template, and so forth) The nucleic acids adhering to the column can be removed by washing with a low salt concentration buffer, a buffer containing a destabilizing agent such as formamide, or by elevating the column temperature
- In one particularly preferred embodiment, the affinity matrix can be used in a method to enrich a sample for unknown RNA sequences (e g expressed sequence tags (ESTs)) The method involves, first providing an affinity matrix bearing a library of oligonucleotide probes specific to known RNA (e g, EST) sequences Then, RNA from undifferentiated and/or unactivated cells and RNA from differentiated or activated or pathological (e g, transformed) or otherwise having a different metabolic state are separately hybridized against the affinity matrices to provide two pools of RNAs lacking the known RNA sequences
- The RNAs from the differentiated (or activated, etc) cells are reverse transcribed to produce cDNAs bearing cleavable PCR priming regions (See, e g, Van Gelder, et al, Proc Natl Acad Sci USA, 87 1663-1667 (1990) and Eberwine et al Proc Natl Acad Sci USA, 89 3010-3014) Similarly, the RNAs from the undifferentiated cells are reverse transcribed to make cDNAs without PCR priming sites The two resulting pools of cDNAs are then combined with the cDNAs from the undifferentiated cells in great excess (e g at least 10 fold excess) At this high concentration, during PCR the cDNAs from the undifferentiated cells will hybridize with complementary sequences from the differentiated cells and form stable duplexes thereby preventing amplification of the corresponding sequences Conversely, those nucleic acids unique to the differentiated cells are differentially amplified Thus, the PCR effectively performs a subtractive hybridization resulting in a nucleic acid sample enriched for unknown ESTs that are characteristic of the activated or differentiated state
- II. Preparation of the Affinity Matrix
- Methods of preparation of the affinity matrices of this invention are illustrated in
FIG. 1 The methods generally involve first identifying the nucleic acids (capture probes) it is desired to include in the affinity matrix Once the capture probes have been identified, corresponding nucleic acid templates can be designed from which the capture probes can be amplified The nucleic acid templates are all attached to a solid support thereby forming a “template array” (seeFIG. 1 , “DNA chip”) In a preferred embodiment, each template nucleic acid is located in a particular preselected region on the solid support Thus, for example, the DNA chip ofFIG. 1 shows an array of “rectangles” where each rectangle contains a different template nucleic acid - The template nucleic acids are amplified en mass (e g, via PCR) to produce a population of different nucleic acids (see
FIG. 1 ) The number of molecules of each species of nucleic acid in the population will be substantially greater than the number of template molecules used to amplify that species The amplified nucleic acids are then attached to a solid support (e g glass or plastic beads) to form an affinity matrix The affinity matrix can be arranged or packaged into a variety of forms In one preferred affinity matrix the matrix material is glass beads having attached capture probes and the beads are packed into a column to thereby produce an affinity column (seeFIG. 1 ) - The method of preparation of affinity matrices can be generally summarized in the following steps
-
- 1) Nucleic acids (capture probes) to be included in the affinity matrix are identified,
- 2) A template array is provided that bears a plurality of different nucleic acids where each different nucleic acid is capable of acting as an amplification template to amplify one of the capture probes,
- 3) The nucleic acid templates in the template array are amplified to provide a population of capture probes where the number of molecules of each capture probe is substantially greater than the number of corresponding template molecules from which the capture probe species was amplified, and
- 4) The capture probes are then attached to a solid support (matrix material) to thereby produce an affinity matrix
Each of these steps is discussed in detail below
- 1) Identification/Selection of Nucleic Acids to Include in the Affinity Matrix.
- As indicated above, the first step in the claimed method of preparing either a free solution containing a multiplicity of preselected oligonucleotides or an affinity matrix of this invention involves determining which oligonucleotides to include in the solution or matrix Once the desired oligonucleotides are identified, an amplification template for each oligonucleotide is designed and the collection of amplification templates form an amplification template array
- One of skill in the art will appreciate that amplification templates can have either the same nucleotide sequence as the desired amplified oligonucleotides or can be complementary to those oligonucleotides The sense of the dominant amplified strand can be controlled by using unequal amounts of primer so that the primer for the undesired strand is effectively rate limiting during the amplification step Methods of determining appropriate template sense and primer ratios are well known to those of skill in the art (see, e g, PCR Protocols a Guide to Methods and Applications, Innis et al, eds Academic Press, Inc N Y 1990) For convenience, when discussing template construction, template sequences capable of amplifying the desired oligonucleotides (capture probes) are discussed as though they have the same sequence as the amplified product, recognizing that the actual corresponding template sequence can be the same or complementary to the ultimate amplified product
- In addition to the template sequence encoding the capture probe, the template nucleic acid can include additional (ancillary) sequences to facilitate amplification and purification of the capture probe Thus, the design of nucleic acid templates can involve both the selection of the capture probe component of the template and the design and inclusion of ancillary sequences Each of these components is described separately below
- a) Identification/Selection of Capture Probe Component of Amplification Template.
- i) Arbitrary Preselected Oligonucleotides.
- One of skill in the art will appreciate that virtually any oligonucleotide can be included in the affinity matrix In a preferred embodiment, however, oligonucleotides are selected that are complementary to a sequence or subsequence of the nucleic acid(s) it is desired to bind to the affinity matrix In addition, capture oligonucleotide sequences are selected to minimize self complementary which may result in hairpin formation, or other secondary structure that may interfere with hybridization In addition, the oligonucleotides can incorporate various base substitutions to reduce secondary structure (e g inosine, 7-deazaguanosine, etc)
- In one embodiment, the oligonucleotide affinity ligands are selected to bind and thus remove nucleic acids (e g mRNAs) that are characteristically overexpressed and thus tend to mask the expression of other nucleic acids that are typically expressed at lower levels Such overexpressed nucleic acids include, but are not limited to, the common “housekeeping” genes such as actin, GAPDH, and other well known constitutively expressed genes
- In another embodiment, the affinity matrix oligonucleotides are selected to hybridize to one or more target nucleic acids it is desired to purify from a sample of biological molecules Thus, for example, where it is desired to isolate a particular set of nucleic acids from a biological sample, the affinity matrix is provided containing oligonucleotides complementary to sequences or subsequences of the nucleic acids it is desired to isolate
- ii) Selecting Oligonucleotide Probes to Bind All Known Sequences.
- In still yet another embodiment, the affinity matrix nucleic acids can be selected to bind to, and thus remove, substantially every known mRNA, cDNA, expressed sequence tag (EST), or other known nucleic acid in a sample, and thus provide a nucleic acid sample enriched for unknown sequences In a preferred embodiment, oligonucleotide “probes” designed for such a selection are chosen to have a relatively uniform melting point (Tm) The probes are also preferably selected to have a low probability of hybridizing to an unknown message and thus have a Tm above a characteristic threshold which is the melting point of the most similar non-selected nucleic acids expected to be in the sample
- A probe selection process embodying the above-identified criteria can be formalized in the following steps
-
- 1) An allowable Tm interval for the probes is selected
- 2) A Tm threshold is selected
- 3) For each known nucleic acid sequence that is to be captured by the affiuty matrix the following steps are performed
- a) All oligonucleotide probes of a preselected length complementary to the sequence and whose Tm falls within the allowable Tm interval are determined
- b) The likelihood of each oligonucleotide probe being a present in an unknown message is calculated,
- c) The oligonucleotide probes are then sorted by likelihood with the least likely probe listed first, and finally
- d) The first probe in the list whose Tm to all other known messages in the sample is below the mismatch Tm is selected for inclusion in the affinity matrix
As indicated above, the allowable Tm interval is arbitrary and chosen largely for convenience Of course, one of skill will appreciate that a narrower Tm will produce fewer suitable probes, while a broader Tm will make optimization of amplification and hybridization conditions more difficult Similarly, a suitable mismatch Tm is also arbitrary Of course, the mismatch Tm must be lower than the Tm interval otherwise the probes comprising the affinity matrix will be unable to specifically discriminate between target nucleic acids and non-target nucleic acids having similar, but not identical, sequences
- The allowable Tm interval (i e the Tm of the selected probes their complementary sequences) typically spans a maximum range of about 30° C., preferably a maximum range of about 20° C., more preferably a maximum range of about 10° C. and most preferably a maximum range of about 5° C. Allowable Tm intervals range from about 30° C. to about 80° C., more preferably from about 35° C. to about 70° C., more preferably from about 40° C. to about 60° C., and most preferably about 45° C. to about 55° C. As indicated above, the mismatch Tm is lower than the low side of the allowable Tm interval, typically at least about 5° C. lower, preferably at least about 10° C. lower, more preferably at least about 15° C. lower and most preferably at least about 20° C. lower than the allowable Tm interval
- As indicated below (in section (2)) above, the oligonucleotides can have a preselected length ranging from 2 up to about 1000 nucleotides, more preferably from about 6 to about 150 nucleotides, most preferably from about 6 to about 50 nucleotides
- Methods of calculating thermal melting points (Tm) of two nucleic acids (e g an oligonucleotide and its complement) are well known to those of skill in the art Detailed calculations are provided for example in Chapter 2 of Laboratory Techniques in Biochemistry and Molecular Biology, Vol 24 Hybridization With Nucleic Acid Probes, P Tijssen, ed Elsevier, N Y, (1993)) (See, also Sambrook, et al, Molecular Cloning a Laboratory Manual, 2nd Ed, Vols 1-3, Cold Spring Harbor Laboratory (1989)), Methods in Enzymology, Vol 152 Guide to Molecular Cloning Techniques, Berger and Kimmel, eds, San Diego Academic Press, Inc (1987), or Current Protocols in Molecular Biology, Ausubel, et al eds, Greene Publishing and Wiley-Interscience, New York (1987))
- In general, the likelihood of an oligonucleotide probe being present in an unknown message is determined by calculating a nucleic acid probability distribution for the particular genome(s) or nucleic acid collection(s) of interest The probability (likelihood) of occurrence of the oligonucleotide probe in that distribution is then determined
- For example, a simple distribution representing the human genome is the frequency of occurrence of each of the bases, a, C, G and T in the human genome Since the human genome is not yet fully sequenced, the complete frequency distribution can be estimated by extrapolation from a sample distribution Thus, for example, the base composition of the human genome can be estimated by selecting all of the human genome sequences listed in GenBank The total number of each nucleotide a, G, C, and T given as NA, NC, NG, and NT, respectively can then be easily totaled The probability of each nucleic acid (p(X) where x is a, G, C, or T) can then be determined as
The likelihood of an oligonucleotide O of length Y where the oligonucleotide is represented as
O=X1−X2−X3−Xy
where X1 is the nucleotide at position 1, X2 is the nucleotide at position 2, and so forth, occurring in the given distribution is then calculated as
p(O)=p(X1)p(X2)p(X3) p(Xy)
In a nucleic acid population where the frequency of occurrence of a, G, C and T is 0 3, 0 3, 0 2 and 0 2, respectively, the probability (p(O)) of an oligonucleotide having the sequence - AAGATT
- is
p(O)=p(A)p(A)p(G)p(A)p(T)p(T)=(0 3)(0 3)(0 3)(0 3)(0 2)(0 2)=0 000324
Such a distribution of course reflects only base composition and lacks sequence information A probability distribution incorporating sequence information can be generated by calculating the marginal probability distribution for a particular base given a certain combination of preceding bases - Thus, for example, the probability distribution of each dinucleotide can be calculated as follows
where p(AA|XA) is the probability of occurrence of the dinucleotide AA given a preceding a, and NAA, NGA, NCA and NTA are the numbers of occurrence of the dinucleotides AA, GA, CA and TA, respectively Similarly, the probability of occurrence of the dinucleotide AT given a preceding C is calculated as
where NAC, NGC, NCC and NTC are the numbers of occurrence of the dinucleotides AC, GC, CC and TC, respectively Other dinucleotide probabilities can be determined in the same manner - The likelihood of an oligonucleotide occurring in the distribution is then calculated as the product of the marginal probability (frequency of occurrence) of its respective dinucleotides given the preceding base Thus, for example the likelihood of oligonucleotide O occurring in the distribution where O is ACGTTACC is
p(O)=p(AC|XC)p(CG|XG)p(GT|XT)p(TT|XT)p(TA|XA)p(AC|XC)p(CC|XC)p(C)
One of skill will readily appreciate that similar distributions can be calculated for trinucleotides, tetranucleotides and so forth to any arbitrary length Each higher order distribution incorporates progressively more sequence information The likelihood of a particular oligonucleotide existing in such a distribution can be calculated as illustrated - The selection of the particular oligonucleotide frequency distribution used to calculate probe likelihoods is essentially arbitrary As indicated above, to a certain extent, higher order distributions capture more sequence information The ability of a particular order probability distribution to accurately reflect likelihood of occurrence of an oligonucleotide mia nucleic acid sample, can be determined by comparing predicted likelihood values for various oligonucleotides with the actual frequency of occurrence of those oligonucleotides in a sample nucleic acid data set The closer the predicted likelihood approximates the actual likelihood, the better is the probability distribution
- Such a comparison can be made, for example, by dividing a collection of sequences (e g the GenBank listing of human cDNAs) in half and using the first half to calculate a nucleic acid frequency distribution and predict the likelihood of occurrence of particular oligonucleotides in the second half of the collection The predicted values can then be compared with the actual frequency of occurrence of the oligonucleotides in the second half of the sequence set and the accuracy of the prediction determined
- iii) Selecting Oligonucleotide Probes to Bind Unknown Sequences
- The method described above provides a means of selecting probes expected to bind to substantially all known sequences in a given nucleic acid sample Conversely, it is possible to select oligonucleotide probes expected to bind to N unknown nucleic acids in a sample, where N is the number of oligonucleotide probes to be selected The selection method basically involves creating a list of all possible probes of a given length, deleting from the list probes that hybridize to known messages, and then selecting the N number of probes that have the greatest likelihood of occurring in an unknown message The method can be formalized as follows
-
- 1) A list (L1) of possible oligonucleotide probes (preferably all probes) of length K is calculated,
- 2) Oligonucleotide probes from list L1 that hybridize to known messages (or messages of interest) are deleted from the list
- 3) The probability of occurrence of each of the oligonucleotide probes of list L1 in a nucleic acid probability distribution is calculated,
- 4) The following steps are repeated until N probes are identified
- a) The list (L1) is sorted from the highest probability to the lowest
- b) The highest probability probe is added to list of selected probes, L2
- Step (4) can additionally include recalculating the probabilities on the condition that the probability distribution contains no nucleic acids complementary to those oligonucleotides already selected
- The list of all possible probes of length K can be calculated in a simple combinatorial manner Thus there are 4 probes of length 1 (a, C, G, T), 16 probes of length 2 (AA, AC, AG, AT, CA, CC, TA, TC, TG, TI) and so forth The distribution of message sequences can be calculated as described above as can the likelihood of occurrence of each probe in L, occurring in the distribution As indicated above k most preferably ranges from about 6 to about 50 nucleotides
- The probability distribution and likelihood is calculated as described above The recalculation conditioned on the fact that no selected probe (L2) is a complementary to an unknown is accomplished again, as described above
- The limitations on thermal melting point can also be imposed on selected probes Thus, only probes having a Tm above a critical threshold and/or probes having a Tm within a specific allowable interval can be selected for inclusion in the affinity matrix
- Either of the above-described probe selection methods can include the additional condition that the Tm of and by one of the selected probes to the other selected probes must be below the mismatch Tm This will prevent cross hybridization between probes comprising the affinity matrix
- While the methods described above use nucleic acid samples (e g sequences selected from a genetic database such as GenBank) to predict the nucleic acid frequency distribution of a “population” (e g the entire genome of a particular species), one of skill will appreciate that where a particular genome is fully sequenced there is no need to calculate the likelihood of occurrence of particular probes Those nucleic acid sequences that it is desired to capture with the affinity matrix can be expressly included
- B) Ancillary Sequences to Facilitate Amplification/Purification.
- As indicated above, the template nucleic acids forming the template array are used as templates for a nucleic acid amplification step (
step 3 of the method described above) In addition to the nucleic acid sequence (or subsequence) encoding the affinity ligands (capture probes) that are to be included in the affinity matrix, the nucleic acid template(s) can additionally include ancillary sequences that facilitate amplification and/or purification - For example, polymerase based amplification systems typically require a double-stranded priming region for binding and initiation of the polymerase The double stranded priming region is typically provided by including, in the amplification reaction mixture, primers that are complementary to a portion of the template that is to be amplified The prunes bind to the template (at primer binding regions which are complementary to the primers) forming a double stranded region in to which the polymerase binds and initiates transcription
- While primers can be selected that specifically hybridize to each of the template nucleic acids such an approach may require a large number of different primers Thus, in a preferred embodiment, the template nucleic acids additionally include terminal subsequences (primer binding sequences) that are common to all of the template nucleic acids All of the constituent nucleic acids can then be amplified with a single set of primers and one set of reaction conditions
- Thus, particularly preferred template nucleic acids comprise, in order, a common first priming domain, a “unique” domain that encodes the affinity ligand (capture probe), and a second common pruning domain (illustrated in
FIG. 1 , as Primer a* binding region, specific affinity ligand, and Primer B* binding region, respectively) The first and second priming domains can be identical thereby allowing the use of a single primer, or alternatively, the pruning domains may have different sequences and thus require two primers for amplification Priming domains can range in length from about 4 to about 50 nucleic acids, preferably from about 4 to about 40 nucleic acids, more preferably from about 4 to about 30 nucleic acids, and most preferably from about 4 to about 20 nucleic acids Particularly preferred priming domains can range from about 6 to about 15 or about 20 nucleic acids in length Priming domains are preferably selected so that the priming domain does not also form a subsequence in any of the unique regions of the templates - Where it is desired to remove the amplification priming domain from the amplification product, the primer domain can additionally corporate a nucleic acid sequence that is recognized by a restriction endonuclease Thus, for example, a six nucleotide priming sequence can include a four base recognition site which when cleaved by a four base cutter leaves a two base tail Longer nucleotide priming sequences can provide longer recognition sites (
e g 5, 6, 7, 10) One of skill will readily appreciate that offset sites can be used allowing a clean cut end Recognition sites and restriction endonucleases are well known to those of skill in the art and selection of particular recognition domains and their corresponding restriction enzyme are well known to those of skill in the art (See, e g Gibco BRL, Grand Island, N.Y., USA, or New England Biolabs, Beverly, Mass., USA for a list of restriction nucleases and their recognition sites) - On occasion, it will be desirable to purify one or more of the nucleic acids amplified from the nucleic acid template array Such purification can be facilitated by incorporating specific (predetermined) nucleic acid “recognition” sequences into the nucleic acid template(s) of the nucleic acid sequences it is desired to purify These nucleic acids can then be isolated from the pool of amplified nucleic acids by use of a nucleic acid affinity column with capture probes complementary to the recognition sequences Thus, for example, a the template(s) can include a poly a tail which will facilitate purification of the amplification product using an oligo dt column Other recognition sequences are, of course, suitable as well Generally a recognition sequence will be selected such that it exists only in the amplified nucleic acids it is desired to purify
- 2) Preparation of a Template Array.
- While the nucleic acid templates can be provided free in solution, in a preferred embodiment the templates are themselves bound to a solid support forming an amplification template array In a particularly preferred embodiment, the amplification template arrays of this invention are high density oligonucleotide arrays comprising at least about 50, generally at least about 100, more generally at least about 500, most generally at least about 1000, preferably at least about 5,000, more preferably at least about 10,000, most preferably at least about 50,000, 100,000, 500,000 or even at least about 1,000,000 different nucleic acid probes Such high density arrays comprise a probe density of generally greater than about 60, more generally greater than about 100, most generally greater than about 600, often greater than about 1000, more often greater than about 5,000, most often greater than about 10,000, preferably greater than about 40,000 more preferably greater than about 100,000, and most preferably greater than about 400,000 different oligonucleotide probes per cm2 The capture probes incorporated into the affinity matrix, and hence the component of the nucleic acid template(s) encoding the affinity ligand (capture probe) itself can range in length from about 2 nucleotides acids up to about 1000 nucleotides acids, generally from about 5 to about 500 nucleotides acids, more generally from about 10 to about 150 nucleotides acids, most generally from about 10 to about 100 nucleotides acids, preferably from about 10 to about 75 nucleotides acids, more preferably from about 10 to about 50 nucleotides, and most preferably from about 15 to about 40 nucleotides in length Where the template nucleic acids include ancillary sequences, as discussed above, the template sequence lengths will be increased accordingly
- Although a planar array surface is preferred, the array may be fabricated on a surface of virtually any shape or even a multiplicity of surfaces Methods of making such amplification template arrays are discussed below
- A) Combinatorial Chemistry
- As indicated above, the nucleic acids acting as “capture” probes in the affinity matrices of this invention are preferably amplified from a multiplicity of amplification templates, more preferably from a group of templates that comprising a high density array of oligonucleotides Methods of forming high density arrays of oligonucleotides, peptides and other polymer sequences with a minimal number of synthetic steps are known The oligonucleotide analogue array can be synthesized on a solid substrate by a variety of methods, including, but not limited to, light-directed chemical coupling, and mechanically directed coupling See Pirrung et al, U.S. Pat. No. 5,143,854 (see also PCT Application No WO 90/15070) and Fodor et al, PCT Publication Nos WO 92/10092 and WO 93/09668 which disclose methods of forming vast arrays of peptides, oligonucleotides and other molecules using, for example, light-directed synthesis techniques, which are incorporated herein by reference See also, Fodor et al, Science, 251, 767-77 (1991) which is incorporated herein by reference These procedures for synthesis of polymer arrays are now referred to as VLSIPS™ procedures Using the VLSIPS™ approach, one heterogenous array of polymers is converted, through simultaneous coupling at a number of reaction sites, into a different heterogenous array See, U.S. application Ser. Nos. 07/796,243 and 07/980,523 which are incorporated herein by reference
- The development of VLSIPS™ technology as described in the above-noted U.S. Pat. No. 5,143,854 and PCT patent publication Nos WO 90/15070 and 92/10092, is considered pioneering technology in the fields of combinatorial synthesis and screening of combinatorial libraries More recently, patent application Ser. No. 08/082,937, filed Jun. 25, 1993 (and incorporated herein by reference) describes methods for making arrays of oligonucleotide probes that can be used to check or determine a partial or complete sequence of a target nucleic acid and to detect the presence of a nucleic acid containing a specific oligonucleotide sequence
- In brief, the light-directed combinatorial synthesis of oligonucleotide arrays on a glass or other surface proceeds using automated phosphoramidite chemistry and chip masking techniques In one specific implementation, a glass surface is derivatized with a silane reagent containing a functional group, e g, a hydroxyl or amine group blocked by a photolabile protecting group Photolysis through a photolithogaphic mask is used selectively to expose functional groups which are then ready to react with incoming 5′-photoprotected nucleoside phosphoramidites The phosphoramidites react only with those sites which are illuminated (and thus exposed by removal of the photolabile blocking group) Thus, the phosphoramidites only add to those areas selectively exposed from the preceding step These steps are repeated until the desired array of sequences have been synthesized on the solid surface Combinatorial synthesis of different oligonucleotide analogues at different locations on the array is determined by the pattern of illumination during synthesis and the order of addition of coupling reagents
- In the event that an oligonucleotide analogue with a polyamide backbone is used in the VLSIPS™ procedure, it is generally inappropriate to use phosphoramidite chemistry to perform the synthetic steps, since the monomers do not attach to one another via a phosphate linkage Instead, peptide synthetic methods are substituted See, e g, Pirrung et al U.S. Pat. No. 5,143,854 which is incorporated herein by reference
- Peptide nucleic acids are commercially available from, e g, Biosearch, Inc (Bedford, Mass.) which comprise a polyamide backbone and the bases found in naturally occurring nucleosides Peptide nucleic acids are capable of binding to nucleic acids with high specificity, and are considered “oligonucleotide analogues” for purposes of this disclosure
- In addition to the foregoing, additional methods which can be used to generate an array of oligonucleotides on a single substrate are described in co-pending application Ser. No. 07/980,523, filed Nov. 20, 1992, and Ser. No. 07/796,243, filed Nov. 22, 1991 and in PCT Publication No WO 93/09668, which are incorporated herein by reference In the methods disclosed in these applications, reagents are delivered to the substrate by either (1) flowing within a channel defined on predefined regions or (2) “spotting” on predefined regions However, other approaches, as well as combinations of spotting and flowing, may be employed In each instance, certain activated regions of the substrate are mechanically separated from other regions when the monomer solutions are delivered to the various reaction sites
- A typical “flow channel” method applied to the compounds and libraries of the present invention can generally be described as follows Diverse polymer sequences are synthesized at selected regions of a substrate or solid support by forming flow channels on a surface of the substrate through which appropriate reagents flow or in which appropriate reagents are placed For example, assume a monomer “a” is to be bound to the substrate in a first group of selected regions If necessary, all or part of the surface of the substrate in all or a part of the selected regions is activated for binding by, for example, flowing appropriate reagents through all or some of the channels, or by washing the entire substrate with appropriate reagents After placement of a channel block on the surface of the substrate, a reagent having the monomer a flows through or is placed in all or some of the channel(s) The channels provide fluid contact to the first selected regions, thereby binding the monomer a on the substrate directly or indirectly (via a spacer) in the first selected regions
- Thereafter, a monomer B is coupled to second selected regions, some of which may be included among the first selected regions The second selected regions will be in fluid contact with a second flow channel(s) through translation, rotation, or replacement of the channel block on the surface of the substrate, through opening or closing a selected valve, or through deposition of a layer of chemical or photoresist If necessary, a step is performed for activating at least the second regions Thereafter, the monomer B is flowed through or placed in the second flow channel(s), binding monomer B at the second selected locations In this particular example, the resulting sequences bound to the substrate at this stage of processing will be, for example, a, B, and AB The process is repeated to form a vast array of sequences of desired length at known locations on the substrate
- After the substrate is activated, monomer a can be flowed through some of the channels, monomer B can be flowed through other channels, a monomer C can be flowed through still other channels, etc In this manner, many or all of the reaction regions are reacted with a monomer before the channel block must be moved or the substrate must be washed and/or reactivated By making use of many or all of the available reaction regions simultaneously, the number of washing and activation steps can be minimized
- One of skill in the art will recognize that there are alternative methods of forming channels or otherwise protecting a portion of the surface of the substrate For example, according to some embodiments, a protective coating such as a hydrophilic or hydrophobic coating (depending upon the nature of the solvent) is utilized over portions of the substrate to be protected, sometimes in combination with materials that facilitate wetting by the reactant solution in other regions In this manner, the flowing solutions are further prevented from passing outside of their designated flow paths
- The “spotting” methods of preparing compounds and libraries of the present invention can be Implemented in much the same manner as the flow channel methods For example, a monomer a can be delivered to and coupled with a first group of reaction regions which have been appropriately activated Thereafter, a monomer B can be delivered to and reacted with a second group of activated reaction regions Unlike the flow channel embodiments described above, reactants are delivered by directly depositing (rather than flowing) relatively small quantities of them in selected regions In some steps, of course, the entire substrate surface can be sprayed or otherwise coated with a solution In preferred embodiments, a dispenser moves from region to region, depositing only as much monomer as necessary at each stop Typical dispensers include a micropipette to deliver the monomer solution to the substrate and a robotic system to control the position of the micropipette with respect to the substrate In other embodiments, the dispenser includes a series of tubes, a manifold, an array of pipettes, or the like so that various reagents can be delivered to the reaction regions simultaneously
- B) Combined Synthetic Methods
- Using the light-directed coupling and mechanically-directed coupling methods described above, one can readily synthesize high density amplification template arrays However, where all of the template nucleic acids include common sequences (e g the primer binding regions) the high density amplification template arrays can be produced using combined (hybrid) synthesis methods Combined methods utilize standard (e g DMT protected phosphoramidite chemistry) for synthesis of the common regions of the templates and light-directed or mechanically-directed methods for the specific binding (affinity ligand) regions of the templates Thus, for example, the first primer binding regions can be synthesized on the solid support according to any standard oligonucleotide synthesis method (e g standard phosphotriester chemistry) The final base added can bear a MenPoc or an Fmoc protecting group allowing the “unique” (affinity ligand) region to be synthesized as described above using any of the light-directed or mechanically-directed coupling methods The last nucleotide added to the “unique” region preferably bears a terminal dimethoxytrityl (DMT) protecting group thereby allowing the second primer binding region to be synthesized using standard oligonucleotide synthesis chemistry
- While any oligonucleotide synthesis method, including solid and liquid phase, phosphite-triester and phosphotriester chemistries, is suitable, oligonucleotide synthesis is preferably carried in solid phase using the solid phase phosphoramidite triester method described by Beaucage et al, Tetrahedron Leas 22 (20) 1859-1862 (1981) The synthesis can be performed manually or using an automated oligonucleotide synthesizer (see, e g Needham-VanDevanter et al Nucleic Acids Res 12 6159-6168 (1984)) Methods of oligonucleotide synthesis are routine and well known to those of skill in the art (See, e g Itakura, U.S. Pat. No. 4,401,796, Caruthers et al, U.S. Pat. Nos. 4,458,066 and 4,500,707, Beaucage et al, Tetrahedron Lett, 22 1859-1862 (1981), Matteucci et al, J Amer Chem Soc, 103 3185-3191 (1981), Caruthers et al, Genetic Engineering, 4 1-17 (1982), Jones, chapter 2, Atkinson et al,
chapter 3, and Sproat et al, chapter 4, in Gait, ed Oligonucleotide Synthesis a Practical Approach, IRL Press, Washington D.C. (1984), Froehler et al, Tetrahedron Lett, 27 469472 (1986), Froehler et al, Nucleic Acids Res, 14 5399-5407 (1986), Sinha et al Tetrahedron Lett, 24 5843-5846 (1983), and Sinha et al, Nucl Acids Res, 12 4539-4557 (1984) - One of skill in the art will appreciate that where different synthesis are to be combined for template synthesis, different protecting groups should also be incorporated Thus, for example, where the first primer binding domain is synthesized using a phosphotriester chemistry, the 5′ hydroxyl group is preferably protected with a dimethoxytrityl (DMT) group The last nucleotide coupled however, is preferably protected with a protecting group compatible with the light-directed or mechanically-directed synthesis methods (e g a Fmoc, Tboc, or MenPoc) with a MenPoc group being most preferred for compatibility with light-directed coupling methods Then the last nucleotide of the unique region added using light-directed synthesis methods will be protected with a DMT group (or other group compatible with the new synthesis chemistry) thereby facilitating synthesis of the second primer binding region using phosphotriester chemistry again
- The common primer binding regions of the template oligonucleotides can be synthesized de novo as described above using the light-directed, mechanically directed or hybrid synthesis methods Alternatively, the complete primer binding regions can be synthesized in a batch process and the completed primer binding region sequence can then be coupled to the solid support forming the amplification template array or to the unique (affinity ligand) region of the templates present in the template array Synthesis according to this approach thus involves coupling the first primer binding region to the substrate of the amplification template array (either directly or through a linker) The primer binding region can be provided with a terminal protecting group, or one can be added afterwards The unique region is then synthesized using light-directed or mechanically-directed coupling methods Finally the second complete primer binding region is covalently linked to the terminus of the unique region Coupling of oligonucleotides simply involves linking the 3′ hydroxyl of one oligonucleotide with the 5′ hydroxyl of a second oligonucleotide (or to an activated site on a solid support or linker) The linkage can be through the formation of a phosphodiester linkage Typically this is accomplished by providing one of the oligonucleotides with an activated or activatable terminal phosphate Methods of providing such phosphate groups and linking oligonucleotides are well known to those of skill in the art (See, e g, WO 85/01051 and WO/90/03382 which are incorporated herein by reference)
- Both the above-described combinatorial synthetic methods as well as the standard synthetic methods result in the production of oligonucleotides linked to a solid support (e g a glass slide or controlled pore glass) via a linker Typically in these methods oligonucleotide synthesis commences by coupling of a nucleotide to a reactive group on a linker which in turn is bound to the solid support The reactive group can be a terminal hydroxyl directly on the solid support, or the 3′ or 5′ hydroxyl of a nucleotide which in turn is bound to the solid support either directly or through a linker Suitable linkers are well known to those of skill in the art (see, e g Gait, et al ed Oligonucleotide Synthesis a Practical Approach, IRL Press, Washington D.C. (1984), U.S. Pat. No. 5,143,854, PCT Application No WO 90/15070, Fodor et al, PCT Publication Nos WO 92/10092 and WO 93/09668, and copending U.S. Ser. No. 08/431,196 filed on Apr. 27, 1995, and Ser. No. 08/374,492, filed on Jan. 17, 1995)
- Where it is desired to perform the subsequent amplification with the template nucleic acids in solution phase, the linkers can be cleaved according to standard methods (e g treatment with concentrated ammonia) Conversely, where the subsequent amplifications are to be performed with the template nucleic acids attached to a solid support, the linker is not cleaved before amplification In a preferred embodiment, the amplification is performed with the template oligonucleotides retained on the solid support The amplification template array can then be reused as a template for a number of amplifications and the production of a large number of affinity matrixes
- 3) Amplification of the Nucleic Acid Templates to Provide a Population of Capture Probes.
- a) Amplification.
- The affinity matrices of this invention comprise at least about 50, preferably at least about 100, more preferably at least about 500, 1000, 5,000, 10,000, 50,000, 100,000, 500,000 and even at least about 1,000,000 different nucleic acid probes One of skill in the art will appreciate that the chemical synthesis of each nucleic acid individually in quantities sufficient to provide an affinity matrix with sufficient loading capacity to isolate useful quantities of target nucleic acids, is an expensive and time-consuming task
- Thus, in a preferred embodiment, the nucleic acid probes are obtained by amplification of the template nucleic acids in the above-described template array The template pool includes at least one nucleic acid that provides the amplification template for each of the nucleic acid sequences that are to be included in the nucleic acid affinity matrix Thus, template arrays can include least about 50, preferably at least about 100, more preferably at least about 500, 1000, 5,000, 10,000, 50,000, 100,000, 500,000 and even at least about 1,000,000 different nucleic acid templates
- The nucleic acids can be amplified by any of the amplification methods well known in the art, which include, but are not limited to polymerase chain reaction (PCR) (Innis, et al, PCR Protocols a guide to Methods and Application Academic Press, Inc San Diego, (1990)), ligase chain reaction (LCR) (see Wu and Wallace, Genomics, 4 560 (1989), Landegren, et al, Science, 241 1077 (1988) and Barringer, et al, Gene, 89 117 (1990)), transcription amplification (see Kwoh, et al, Proc Natl Acad Sci (USA), 86 1173 (1989)), and self-sustained sequence replication (see Guatelli, et al, Proc Nat Acad Sci (USA), 87 1874(1990))
- Amplification of the nucleic acids comprising the template pool can be performed in solution or with the template nucleic acids anchored to a solid support (e g, a glass slide) and thereby forming a template array In a preferred embodiment, amplification is by polymerase chain reaction (PCR) PCR amplification methods are well known to those of skill in the art Basic amplification conditions can be found in a wide variety of references such as PCR Protocols a Guide to Methods and Applications, Innis et al, eds Academic Press, Inc New York (1990)
- One of skill will appreciate that amplification can be optimized for particular primer/template array combinations Optimization typically involves adjusting magnesium ion concentration, buffer composition (e g KCl and NaCl ion concentration and buffer pH), and the temperature and length of time allowed for primer annealing, extension and denaturation Methods of optimizing amplification protocols are routine and well known to those of skill in the art (see, e g Chapter 1 in PCR Protocols a Guide to Methods and Applications, Innis et al, eds Academic Press, Inc New York (1990)) In a standard and suitable PCR protocol, the reaction mix includes about 20 pmol of each primer (Tm>55° C. preferred), 20 mM Tris-HCl (pH 8 3) (20° C.), 1 5 mM MgCl2, 25 mM KCl, 0 05% Tween 20, 100 μg/ml autoclaved gelatin or nuclease-free bovine serum albumin, 50 μM each dNTP, and 2 units of Taq DNA polymerase
- The amplification is typically run through enough cycles to provide the desired amount of amplified product (capture probe) In a preferred embodiment, the amplification will be cycled enough to produce at least a 2 fold, generally at least a 5 fold, more generally at least a 10 fold, preferably at least a 100 fold, more preferably at least a 1000 fold, and most preferably at least a 10,000 fold amplification Where most of the amplified nucleic acid pool is incorporated into the affinity matrix, the matrix will thus contain at least a 2 fold, generally at least a 5 fold, more generally at least a 10 fold, preferably at least a 100 fold, more preferably at least a 1000 fold, and most preferably at least a 10,000 fold more nucleic acid molecules of each species than the original nucleic acid template array
- A standard amplification will involve 20 to 40 cycles, more preferably about 25 to 35 cycles In a preferred embodiment cycling is carried out for about 25 to about 35 cycles using the following temperature profile
Denaturation about 96° C., 15 seconds (a longer initial time is usually desirable), Primer annealing, about 55° C., 30 seconds, and Primer Extension about 72° C., 1 5 minutes
Cycling preferably concludes with a final extension at about 72° C. for 5 minutes Reactions can be stopped by chilling to 4° C. and/or by addition of EDTA to 10 mM - B) Post Amplification Processing.
- While the amplified nucleic acid pool can be used directly, in a preferred embodiment, the amplified nucleic acids are purified away from reaction components (e g incomplete amplification products, nucleotide triphosphates, etc) Means of purifying nucleic acid amplification products are well known to those of skill in the art Typically the amplification products are the largest nucleic acids in the reaction mixture and purification techniques based on molecule size are highly effective Such methods include, but are not limited to gel electrophoresis, high performance liquid chromatography (HPLC), affinity chromatography (e g using an affinity column complementary to the primer binding region), capillary electrophoresis, density gradient centrifugation, and the like Particularly preferred is HPLC using an anion exchange column (e g mono Q from Pharmacia, Piscataway, N.J.)
- Where the amplified nucleic acids include restriction sites (e g, for removal of the primer regions) and the amplified nucleic acids are to be cleaved at the reaction sites before use the cleavage reaction can be performed before or after purification However, in a preferred embodiment, it is desirable to cleave the amplification products prior to purification so that the desired cleaved product (e g, capture probes) are purified away from the undesired sequences (e g, primer binding regions) in the single purification step described above
- Cleavage of the amplified nucleic acids containing restriction sites Is accomplished according to standard methods well known to those of skill in the art Typically, the amplification product is combined with the restriction endonuclease specific for the cleavage site under conditions (e g, temperature, pH) where the restriction endonuclease is active Suitable reaction conditions for each particular restriction endonuclease are provided by the supplier or manufacturer
- 3) Attachment of the Amplified Nucleic Acids to a Solid Support to Produce an Affinity Matrix
- The affinity matrices of this invention can be formulated with virtually any solid material or gel that does not substantially interfere with hybridization of the oligonucleotides Suitable matrix materials include paper, glasses, ceramics, metals, metalloids, polacryloylmorpholide, various plastics and plastic copolymers such as Nylon™, Teflon™, polyethylene, polypropylene, poly(4-methylbutene), polystyrene, polystyrene, polystyrene/latex, polymethacrylate, poly(ethylene terephthalate), rayon, nylon, poly(vinyl butyrate), polyvinylidene difluoride (PVDF), silicones, polyformaldehyde, cellulose, cellulose acetate, nitrocellulose, and the like Materials that typically bind nucleic acids (e g cellulose) are suitable, however, in a preferred embodiment, an affinity matrix composed of such materials is preferably prehybridized with a blocking nucleic acid (e g sperm DNA or C0t-1 DNA) to reduce non-specific binding
- The affinity matrix can be loaded with virtually any amount of oligonucleotide affinity ligand, the loading being only limited by available binding sites for attachment of the ligand and thus, only limited by the available amount of solid or gel support
- The affinity matrix can take any form that is convenient including beads, porous beads, crushed particles, membranes, tubing, planar surfaces, etc Preferred matrix materials are particulate (e g beads) thereby providing increased surface area for attachment of affinity ligands Particularly preferred matrix materials can be porous (fenestrated) highly convoluted and/or rugose (e g controlled pore glass, folded membranes, etc)
- Methods of attaching oligonucleotides to solid supports (matrix materials) are well known to those of skill in the art For example, in a preferred embodiment, the primers used in the amplification can be provided with a conjugated biotin or streptavidin The amplified nucleic acids will then bear the biotin or streptavidin and can be coupled to a solid support bearing avidin (streptavidin) or biotin respectively
- Alternatively, the nucleic acid can be covalently coupled to the solid support either directly via an activated group (e g a hydroxyl, a carboxyl) or through a linker that provides reactive moieties that bind to the oligonucleotide and to the matrix material respectively Linkers suitable for attaching nucleic acids to matrix materials are also well known Generally linkers are either hetero- or homo-bifunctional molecules that contain two or more reactive sites that may each form a covalent bond with the respective binding partner (the matrix material or the nucleic acid) For example, the probe oligonucleotides may be joined by a peptide linker, by a straight or branched chain carbon chan linker, or by a heterocyclic carbon Heterobifunctional cross linking reagents such as active esters of N-ethylmaleimide have been widely used See, for example, Lerner et al Proc Nat Acad Sci (USA), 78 3403-3407 (1981) and Kitagawa et al J Biochem, 79 233-236 (1976) Other linkers, such as those used in the synthesis of nucleic acids are also suitable (see, e g PCT Publication WO 85/01051, Pochet et al Tetrahedron 43 3481-3490 (1987), Schwyzer et al, Helv Chim Acta, 67 1316-1327 (1984), Gait, ed Oligonucleotide Synthesis a Practical Approach, IRL Press, Washington D.C. (1984))
- As indicated above, any material to which the oligonucleotide can be bound and which is resistant to nucleic acid hybridization reagents (e g Tris-HCl, SSC, etc) and temperatures (e g 30° C. to 80° C.) and does not substantially interfere with the oligonucleotide hybridization is suitable for use as a matrix material Particularly preferred matrix materials include glass beads, controlled pore glass, and various polymeric resins such as polystyrene, polystyrene/latex, and the like
- In a preferred embodiment, the amplified nucleic acids are purified away from the other components of the amplification mixture (e g triphosphates, truncated amplification products, etc) prior to attachment to the matrix material Methods of purifying nucleic acids are well known to those of skill in the art and described above
m section 3 - IV. Hybridization Conditions,
- The affinity matrices of this invention rely on hybridization between the nucleic acids comprising the affinity matrix and any target nucleic acids that may be present in the sample to specifically bind to and remove the target nucleic acids from the sample Nucleic acid hybridization simply involves contacting the oligonucleotide probes of the affinity matrix and the target nucleic acid under conditions where the probe and its complementary target can form stable hybrid duplexes through complementary base pairing The nucleic acids that do not form hybrid duplexes are then washed away leaving the hybridized nucleic acids bound to the affinity matrix Where the bound nucleic acids are to be retrieved, the duplexes can be denatured (e g by increasing temperature, adding formamide or decreasing salt) and the freed nucleic acids recovered Alternatively the sample contacted with the affinity matrix can be recovered and will be lacking those nucleic acids captured and removed by the affinity matrix
- It is generally recognized that nucleic acids are denatured by increasing the temperature or decreasing the salt concentration of the buffer containing the nucleic acids Under low stringency conditions (e g, low temperature and/or high salt) hybrid duplexes (e g, DNA DNA, RNA RNA, or RNA DNA) will form even where the annealed sequences are not perfectly complementary Thus specificity of hybridization is reduced at lower stringency Conversely, at higher stringency (e g, higher temperature or lower salt) successful hybridization requires fewer mismatches
- One of skill in the art will appreciate that hybridization conditions may be selected to provide any degree of stringency In a preferred embodiment, hybridization is performed at low stringency in this case in 6×SSPE-T at 37° C. (0 005% Triton X-100) to ensure hybridization and then subsequent washes are performed at higher stringency (e g, 1×SSPE-T at 37° C.) to eliminate mismatched hybrid duplexes Successive washes may be performed at increasingly higher stringency (e g, down to as low as 0 25×SSPE-T at 37° C. to 50° C.) until a desired level of hybridization specificity is obtained Stringency can also be increased by addition of agents such as formamide Hybridization specificity may be evaluated by comparison of hybridization to the sample nucleic acids with hybridization to the various controls that can be present (e g, expression level control such as mRNAs spiked into the sample at known concentrations, etc)
- In general, there is a tradeoff between hybridization specificity (stringency) and signal intensity Thus, in a preferred embodiment, the wash is performed at the highest stringency that produces consistent results or achieves maximum specific removal of the target nucleic acids from the sample
- The stability of duplexes formed between RNAs or DNAs are generally in the order of RNA RNA>RNA DNA>DNA DNA, in solution Long probes have better duplex stability with a target, but poorer mismatch discrimination than shorter probes (mismatch discrimination refers to the measured hybridization signal ratio between a perfect match probe and a single base mismatch probe) Shorter probes (e g, 8-mers) discriminate mismatches very well, but the overall duplex stability is low
- Altering the thermal stability (Tm) of the duplex formed between the target and the probe using, e g, known oligonucleotide analogues allows for optimization of duplex stability and mismatch discrimination One useful aspect of altering the Tm arises from the fact that adenine-thymine (a-T) duplexes have a lower Tm than guanine-cytosine (G-C) duplexes, due in part to the fact that the a-T duplexes have 2 hydrogen bonds per base-pair, while the G-C duplexes have 3 hydrogen bonds per base pair In heterogeneous oligonucleotide matrices in which there is a non-uniform distribution of bases, it is not generally possible to optimize hybridization for each oligonucleotide probe simultaneously Thus, in some embodiments, it is desirable to selectively destabilize GE duplexes and/or to increase the stability of a-T duplexes This can be accomplished, e g, by substituting guanine residues in the probes of a matrix which form G-C duplexes with hypoxanthine, or by substituting adenine residues in probes which form a-T duplexes with 2,6 diaminopurine or by using the salt tetramethyl ammonium chloride (TMACI) in place of NaCl
- Altered duplex stability conferred by using oligonucleotide analogue probes can be ascertained by following, e g, fluorescence signal intensity of oligonucleotide analogue arrays hybridized with a target oligonucleotide over time The data allow optimization of specific hybridization conditions at, e g, room temperature (for simplified diagnostic applications in the future)
- Another way of verifying altered duplex stability is by following the signal intensity generated upon hybridization with a labeled sample with time Previous experiments using DNA targets and DNA chips have shown that signal intensity increases with time, and that the more stable duplexes generate higher signal intensities faster than less stable duplexes The signals reach a plateau or “saturate” after a certain amount of time due to all of the binding sites becoming occupied These data allow for optimization of hybridization, and determination of the best conditions at a specified temperature
- Methods of optimizing hybridization conditions are well known to those of skill in the art (see, e g, Laboratory Techniques in Biochemistry and Molecular Biology, Vol 24 hybridization With Nucleic Acid Probes, P Tijssen, ed Elsevier, N Y, (1993))
- In a preferred embodiment, the affinity matrix is packed into a columnar casing The sample is then applied to the affinity matrix (e g injected onto a column or applied to a column by a pump such as a sampling pump driven by an autosampler) The affinity matrix (e g affinity column) bearing the sample is subjected to conditions under which the nucleic acid probes comprising the affinity matrix hybridize specifically with complementary target nucleic acids Such conditions are accomplished by maintaining appropriate pH, salt and temperature conditions to facilitate hybridization as discussed above
- It is understood that the embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes
Claims (2)
1. A method of making a nucleic acid pool comprising a plurality of different nucleic acids, said method comprising the steps of:
a) providing a nucleic acid amplification template array comprising a surface to which are attached at least 20 oligonucleotides having different predetermined nucleic acid sequences, and wherein:
i) each different oligonucleotide is localized in a predetermined region of said surface;
ii) the density of said oligonucleotides is greater than about 60 different oligonucleotides per 1 cm2; and
iii) said different oligonucleotides have an identical terminal 5′ nucleic acid sequence;
b) amplifying said multiplicity of oligonucleotides at least about 10 fold to provide said nucleic acid pool.
2-40. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/360,146 US20060204991A1 (en) | 1996-03-11 | 2006-02-22 | Nucleic acid affinity columns |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1323196P | 1996-03-11 | 1996-03-11 | |
US08/815,395 US6013440A (en) | 1996-03-11 | 1997-03-10 | Nucleic acid affinity columns |
US09/429,521 US6280950B1 (en) | 1996-03-11 | 1999-10-28 | Nucleic acid affinity columns |
US09/910,223 US6440677B2 (en) | 1996-03-11 | 2001-07-20 | Nucleic acid affinity columns |
US10/219,006 US6828104B2 (en) | 1996-03-11 | 2002-08-14 | Nucleic acid affinity columns |
US10/984,127 US20050118633A1 (en) | 1996-03-11 | 2004-11-08 | Nucleic acid affinity columns |
US11/360,146 US20060204991A1 (en) | 1996-03-11 | 2006-02-22 | Nucleic acid affinity columns |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/984,127 Continuation US20050118633A1 (en) | 1996-03-11 | 2004-11-08 | Nucleic acid affinity columns |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060204991A1 true US20060204991A1 (en) | 2006-09-14 |
Family
ID=26684593
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/815,395 Expired - Lifetime US6013440A (en) | 1996-03-11 | 1997-03-10 | Nucleic acid affinity columns |
US09/429,521 Expired - Lifetime US6280950B1 (en) | 1996-03-11 | 1999-10-28 | Nucleic acid affinity columns |
US09/910,223 Expired - Lifetime US6440677B2 (en) | 1996-03-11 | 2001-07-20 | Nucleic acid affinity columns |
US10/219,006 Expired - Lifetime US6828104B2 (en) | 1996-03-11 | 2002-08-14 | Nucleic acid affinity columns |
US10/984,127 Abandoned US20050118633A1 (en) | 1996-03-11 | 2004-11-08 | Nucleic acid affinity columns |
US11/360,146 Abandoned US20060204991A1 (en) | 1996-03-11 | 2006-02-22 | Nucleic acid affinity columns |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/815,395 Expired - Lifetime US6013440A (en) | 1996-03-11 | 1997-03-10 | Nucleic acid affinity columns |
US09/429,521 Expired - Lifetime US6280950B1 (en) | 1996-03-11 | 1999-10-28 | Nucleic acid affinity columns |
US09/910,223 Expired - Lifetime US6440677B2 (en) | 1996-03-11 | 2001-07-20 | Nucleic acid affinity columns |
US10/219,006 Expired - Lifetime US6828104B2 (en) | 1996-03-11 | 2002-08-14 | Nucleic acid affinity columns |
US10/984,127 Abandoned US20050118633A1 (en) | 1996-03-11 | 2004-11-08 | Nucleic acid affinity columns |
Country Status (1)
Country | Link |
---|---|
US (6) | US6013440A (en) |
Families Citing this family (321)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5846717A (en) * | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
US7323298B1 (en) * | 1994-06-17 | 2008-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Microarray for determining the relative abundances of polynuceotide sequences |
US5766891A (en) * | 1994-12-19 | 1998-06-16 | Sloan-Kettering Institute For Cancer Research | Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase |
US20110028350A1 (en) * | 1995-12-15 | 2011-02-03 | Affymetrix, Inc. | Photocleavable protecting groups |
US6147205A (en) * | 1995-12-15 | 2000-11-14 | Affymetrix, Inc. | Photocleavable protecting groups and methods for their use |
US7432048B2 (en) * | 1996-11-29 | 2008-10-07 | Third Wave Technologies, Inc. | Reactions on a solid surface |
US7195871B2 (en) * | 1996-01-24 | 2007-03-27 | Third Wave Technologies, Inc | Methods and compositions for detecting target sequences |
US6013440A (en) * | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
US7078035B2 (en) * | 1997-08-13 | 2006-07-18 | Diversa Corporation | Phytases, nucleic acids encoding them and methods for making and using them |
ATE341621T1 (en) * | 1997-10-24 | 2006-10-15 | Invitrogen Corp | RECOMBINATORY CLONING USING NUCLIC ACIDS HAVING RECOMBINATION SITE |
US6979728B2 (en) * | 1998-05-04 | 2005-12-27 | Baylor College Of Medicine | Articles of manufacture and methods for array based analysis of biological molecules |
US6908770B1 (en) * | 1998-07-16 | 2005-06-21 | Board Of Regents, The University Of Texas System | Fluid based analysis of multiple analytes by a sensor array |
US7034143B1 (en) * | 1998-10-13 | 2006-04-25 | Brown University Research Foundation | Systems and methods for sequencing by hybridization |
US7071324B2 (en) * | 1998-10-13 | 2006-07-04 | Brown University Research Foundation | Systems and methods for sequencing by hybridization |
DE19854946C2 (en) * | 1998-11-27 | 2002-01-03 | Guenter Von Kiedrowski | Cloning and copying on surfaces |
ATE334197T1 (en) * | 1999-02-19 | 2006-08-15 | Febit Biotech Gmbh | METHOD FOR PRODUCING POLYMERS |
AU5785400A (en) | 1999-07-02 | 2001-01-22 | Symyx Technologies, Inc. | Polymer brushes for immobilizing molecules to a surface or substrate, where the polymers have water-soluble or water-dispersible segments and probes bonded thereto |
EP1204859B1 (en) | 1999-07-16 | 2006-11-22 | The Board Of Regents, The University Of Texas System | Method and apparatus for the delivery of samples to a chemical sensor array |
US6653151B2 (en) | 1999-07-30 | 2003-11-25 | Large Scale Proteomics Corporation | Dry deposition of materials for microarrays using matrix displacement |
US6713309B1 (en) | 1999-07-30 | 2004-03-30 | Large Scale Proteomics Corporation | Microarrays and their manufacture |
US7179638B2 (en) | 1999-07-30 | 2007-02-20 | Large Scale Biology Corporation | Microarrays and their manufacture by slicing |
DK1218545T3 (en) | 1999-08-18 | 2012-02-20 | Illumina Inc | Methods of Preparation of Oligonucleotide Solutions |
US6492118B1 (en) | 1999-08-27 | 2002-12-10 | Matrix Technologies Corporation | Methods of immobilizing ligands on solid supports |
AU2246601A (en) | 1999-08-30 | 2001-04-10 | Illumina, Inc. | Methods for improving signal detection from an array |
US7211390B2 (en) * | 1999-09-16 | 2007-05-01 | 454 Life Sciences Corporation | Method of sequencing a nucleic acid |
US7244559B2 (en) * | 1999-09-16 | 2007-07-17 | 454 Life Sciences Corporation | Method of sequencing a nucleic acid |
US6844151B1 (en) * | 1999-09-29 | 2005-01-18 | Oligos Etc. Inc. | Methods for production of arrays with modified oligonucleotide and polynucleotide compositions |
DE10000629C5 (en) * | 2000-01-10 | 2010-06-02 | november Aktiengesellschaft, Gesellschaft für Molekulare Medizin | Method of identifying a label applied to a solid |
WO2001055702A1 (en) | 2000-01-31 | 2001-08-02 | Board Of Regents, The University Of Texas System | Portable sensor array system |
US8076063B2 (en) * | 2000-02-07 | 2011-12-13 | Illumina, Inc. | Multiplexed methylation detection methods |
EP1990428B1 (en) * | 2000-02-07 | 2010-12-22 | Illumina, Inc. | Nucleic acid detection methods using universal priming |
US7611869B2 (en) * | 2000-02-07 | 2009-11-03 | Illumina, Inc. | Multiplexed methylation detection methods |
US7582420B2 (en) | 2001-07-12 | 2009-09-01 | Illumina, Inc. | Multiplex nucleic acid reactions |
US7955794B2 (en) | 2000-09-21 | 2011-06-07 | Illumina, Inc. | Multiplex nucleic acid reactions |
US6770441B2 (en) * | 2000-02-10 | 2004-08-03 | Illumina, Inc. | Array compositions and methods of making same |
US20020110901A1 (en) * | 2000-02-18 | 2002-08-15 | Aspira Biosystems, Inc. | Compositions and methods for surface imprinting |
JP2004507207A (en) * | 2000-02-18 | 2004-03-11 | サイエンス アプリケイションズ インターナショナル コーポレイション | Method for detecting a biological entity in a sample |
WO2001062943A1 (en) * | 2000-02-25 | 2001-08-30 | Invitrogen Corporation | Topoisomerase linker-mediated amplification methods |
US6884578B2 (en) | 2000-03-31 | 2005-04-26 | Affymetrix, Inc. | Genes differentially expressed in secretory versus proliferative endometrium |
US7455966B1 (en) | 2000-05-01 | 2008-11-25 | Science Applications International Corporation | System and method for detecting a biological entity in a water sample |
US6605451B1 (en) | 2000-06-06 | 2003-08-12 | Xtrana, Inc. | Methods and devices for multiplexing amplification reactions |
US7087414B2 (en) * | 2000-06-06 | 2006-08-08 | Applera Corporation | Methods and devices for multiplexing amplification reactions |
TW513485B (en) * | 2000-07-10 | 2002-12-11 | Ind Tech Res Inst | On-spot hydrophilic enhanced slide and preparation thereof |
EP1180548B1 (en) * | 2000-07-31 | 2005-11-02 | Agilent Technologies, Inc. (a Delaware corporation) | Array based methods for synthesizing nucleic acid mixtures |
US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
NZ524135A (en) * | 2000-08-21 | 2004-08-27 | Invitrogen Corp | Methods and reagents for molecular cloning |
US7108969B1 (en) | 2000-09-08 | 2006-09-19 | Affymetrix, Inc. | Methods for detecting and diagnosing oral cancer |
AU2001292142A1 (en) * | 2000-09-11 | 2002-03-22 | Affymetrix, Inc. | Photocleavable protecting groups |
EP2333543B1 (en) | 2000-09-26 | 2018-01-10 | Health Research, Incorporated | Analysis of hiv-1 coreceptor use in the clinical care of hiv-1 infected patients |
US20020150887A1 (en) * | 2000-11-09 | 2002-10-17 | National Institute Of Advanced Industrial Science And Technology | Methods and nucleic acid probes for molecular genetic analysis of polluted environments and environmental samples |
AU2002246541A1 (en) * | 2000-11-28 | 2002-08-06 | Promega Corporation | Rna polymers and uses thereof |
US7435390B2 (en) * | 2001-01-26 | 2008-10-14 | Third Wave Technologies, Inc. | Nucleic acid synthesizers |
US6932943B1 (en) | 2001-01-26 | 2005-08-23 | Third Wave Technologies | Nucleic acid synthesizers |
US20030072689A1 (en) * | 2001-08-15 | 2003-04-17 | Third Wave Technologies, Inc. | Polymer synthesizer |
US20060008817A1 (en) * | 2000-12-08 | 2006-01-12 | Invitrogen Corporation | Methods and compositions for generating recombinant nucleic acid molecules |
WO2002061034A2 (en) * | 2000-12-08 | 2002-08-08 | Invitrogen Corporation | Compositions and methods for rapidly generating recombinant nucleic acid molecules |
US7205161B2 (en) * | 2001-01-10 | 2007-04-17 | Symyx Technologies, Inc. | Polymer brushes for immobilizing molecules to a surface or substrate having improved stability |
US20020110904A1 (en) * | 2001-01-18 | 2002-08-15 | Nelson Randall W. | Integrated system for analysis of biomolecules |
JP2004529323A (en) * | 2001-01-31 | 2004-09-24 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Method and apparatus for confining material in a micromachined chemical sensor array |
US20030003436A1 (en) * | 2001-02-05 | 2003-01-02 | Willson C. Grant | Use of mesoscale self-assembly and recognition to effect delivery of sensing reagent for arrayed sensors |
DE10119468A1 (en) * | 2001-04-12 | 2002-10-24 | Epigenomics Ag | Selective enrichment of specific polymerase chain reaction products, useful e.g. for diagnosis, by cycles of hybridization to an array and re-amplification |
US7138506B2 (en) * | 2001-05-09 | 2006-11-21 | Genetic Id, Na, Inc. | Universal microarray system |
US20030032681A1 (en) * | 2001-05-18 | 2003-02-13 | The Regents Of The University Of Clifornia | Super-hydrophobic fluorine containing aerogels |
US20030009294A1 (en) * | 2001-06-07 | 2003-01-09 | Jill Cheng | Integrated system for gene expression analysis |
US7297553B2 (en) * | 2002-05-28 | 2007-11-20 | Nanosphere, Inc. | Method for attachment of silylated molecules to glass surfaces |
WO2003006676A2 (en) * | 2001-07-13 | 2003-01-23 | Nanosphere, Inc. | Method for immobilizing molecules onto surfaces |
US10539561B1 (en) | 2001-08-30 | 2020-01-21 | Customarray, Inc. | Enzyme-amplified redox microarray detection process |
US20050032060A1 (en) * | 2001-08-31 | 2005-02-10 | Shishir Shah | Arrays comprising pre-labeled biological molecules and methods for making and using these arrays |
DE10149947A1 (en) | 2001-10-10 | 2003-04-17 | Febit Ferrarius Biotech Gmbh | Isolating target molecules, useful for separating e.g. nucleic acids for therapy or diagnosis, comprises passing the molecules through a microfluidics system that carries specific receptors |
US7439346B2 (en) * | 2001-10-12 | 2008-10-21 | Perkinelmer Las Inc. | Nucleic acids arrays and methods of use therefor |
JP2005519634A (en) | 2001-10-12 | 2005-07-07 | スペクトラル ジェノミクス、インク. | Nucleic acid compositions and arrays and methods using them |
US20030175709A1 (en) * | 2001-12-20 | 2003-09-18 | Murphy George L. | Method and system for depleting rRNA populations |
WO2003066906A2 (en) * | 2002-02-07 | 2003-08-14 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Diagnostic microarray and method of use thereof |
US6916621B2 (en) * | 2002-03-27 | 2005-07-12 | Spectral Genomics, Inc. | Methods for array-based comparitive binding assays |
US7687256B2 (en) * | 2002-04-11 | 2010-03-30 | Spire Corporation | Surface activated biochip |
US7226771B2 (en) | 2002-04-19 | 2007-06-05 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
CA2481411C (en) | 2002-04-19 | 2016-06-14 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
AU2003228711C1 (en) | 2002-04-26 | 2010-01-07 | Board Of Regents, The University Of Texas System | Method and system for the detection of cardiac risk factors |
US9388459B2 (en) * | 2002-06-17 | 2016-07-12 | Affymetrix, Inc. | Methods for genotyping |
US7108976B2 (en) * | 2002-06-17 | 2006-09-19 | Affymetrix, Inc. | Complexity management of genomic DNA by locus specific amplification |
EP1543128A4 (en) * | 2002-07-18 | 2008-02-20 | Invitrogen Corp | Viral vectors containing recombination sites |
US7563600B2 (en) * | 2002-09-12 | 2009-07-21 | Combimatrix Corporation | Microarray synthesis and assembly of gene-length polynucleotides |
CA2503905A1 (en) * | 2002-09-16 | 2004-03-25 | Plexxikon, Inc. | Crystal structure of pim-1 kinase |
US20040259105A1 (en) * | 2002-10-03 | 2004-12-23 | Jian-Bing Fan | Multiplex nucleic acid analysis using archived or fixed samples |
US7459273B2 (en) * | 2002-10-04 | 2008-12-02 | Affymetrix, Inc. | Methods for genotyping selected polymorphism |
US20060127907A1 (en) * | 2002-11-07 | 2006-06-15 | Daiichi Pure Chemicals Co., Ltd. | Method of detecting gene mutation |
AU2003298706A1 (en) | 2002-12-04 | 2004-06-23 | Applera Corporation | Multiplex amplification of polynucleotides |
US8216854B2 (en) * | 2003-01-07 | 2012-07-10 | Biotex, Inc. | Device and method for measuring analytes |
US20050048573A1 (en) * | 2003-02-03 | 2005-03-03 | Plexxikon, Inc. | PDE5A crystal structure and uses |
US20040152085A1 (en) * | 2003-02-04 | 2004-08-05 | Veridian Systems Division | Surface for collection and/or purification of nucleic acids |
US7223851B2 (en) * | 2003-02-06 | 2007-05-29 | General Dynamics Advanced Information Systems, Inc. | Nucleic acid-binding polymers |
US20050170431A1 (en) * | 2003-02-28 | 2005-08-04 | Plexxikon, Inc. | PYK2 crystal structure and uses |
CN104388449A (en) | 2003-03-06 | 2015-03-04 | 维莱尼姆公司 | Amylases, nucleic acids encoding them and methods for making and using them |
CA2889013C (en) | 2003-03-07 | 2018-07-17 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
MXPA05010681A (en) | 2003-04-04 | 2005-12-15 | Diversa Corp | Pectate lyases, nucleic acids encoding them and methods for making and using them. |
US7833714B1 (en) | 2003-04-11 | 2010-11-16 | Affymetrix, Inc. | Combinatorial affinity selection |
WO2004097371A2 (en) * | 2003-04-25 | 2004-11-11 | Board Of Regents, The University Of Texas System | System and method for the detection of analytes |
US7300755B1 (en) * | 2003-05-12 | 2007-11-27 | Fred Hutchinson Cancer Research Center | Methods for haplotyping genomic DNA |
US7651850B2 (en) * | 2003-05-16 | 2010-01-26 | Board Of Regents, The University Of Texas System | Image and part recognition technology |
US9317922B2 (en) | 2003-05-16 | 2016-04-19 | Board Of Regents The University Of Texas System | Image and part recognition technology |
US8133670B2 (en) * | 2003-06-13 | 2012-03-13 | Cold Spring Harbor Laboratory | Method for making populations of defined nucleic acid molecules |
CN108486086A (en) | 2003-07-02 | 2018-09-04 | 维莱尼姆公司 | Dextranase, encode they nucleic acid and preparation and use their method |
US20050079548A1 (en) * | 2003-07-07 | 2005-04-14 | Plexxikon, Inc. | Ligand development using PDE4B crystal structures |
US8114978B2 (en) | 2003-08-05 | 2012-02-14 | Affymetrix, Inc. | Methods for genotyping selected polymorphism |
WO2005021714A2 (en) | 2003-08-11 | 2005-03-10 | Diversa Corporation | Laccases, nucleic acids encoding them and methods for making and using them |
US20050106594A1 (en) * | 2003-08-22 | 2005-05-19 | Andrew Ellington | In vitro selection of aptamer beacons |
WO2005026686A2 (en) * | 2003-09-09 | 2005-03-24 | Compass Genetics, Llc | Multiplexed analytical platform |
US20050164300A1 (en) * | 2003-09-15 | 2005-07-28 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
JP2007515947A (en) * | 2003-10-30 | 2007-06-21 | タフツ−ニュー イングランド メディカル センター | Prenatal diagnosis using acellular fetal DNA in amniotic fluid |
DE10353887A1 (en) * | 2003-11-18 | 2005-06-16 | Febit Ag | Highly parallel matrix-based DNA synthesizer |
EP1697534B1 (en) * | 2003-12-01 | 2010-06-02 | Life Technologies Corporation | Nucleic acid molecules containing recombination sites and methods of using the same |
US20070066641A1 (en) * | 2003-12-19 | 2007-03-22 | Prabha Ibrahim | Compounds and methods for development of RET modulators |
PL1696920T3 (en) * | 2003-12-19 | 2015-03-31 | Plexxikon Inc | Compounds and methods for development of ret modulators |
EP1713936B1 (en) * | 2004-02-12 | 2009-12-09 | Population Genetics Technologies Ltd Corporation of Great Britain | Genetic analysis by sequence-specific sorting |
JP2007534320A (en) * | 2004-02-27 | 2007-11-29 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Polynucleotide synthesis method |
US8105849B2 (en) * | 2004-02-27 | 2012-01-31 | Board Of Regents, The University Of Texas System | Integration of fluids and reagents into self-contained cartridges containing sensor elements |
US8101431B2 (en) * | 2004-02-27 | 2012-01-24 | Board Of Regents, The University Of Texas System | Integration of fluids and reagents into self-contained cartridges containing sensor elements and reagent delivery systems |
EP1742627A4 (en) | 2004-05-06 | 2009-08-26 | Plexxikon Inc | Pde4b inhibitors and uses therefor |
EP1766061B1 (en) * | 2004-05-20 | 2013-07-17 | Quest Diagnostics Investments Incorporated | Single label comparative hybridization |
ES2540728T3 (en) | 2004-06-16 | 2015-07-13 | Dsm Ip Assets B.V. | Method for enzymatic discoloration of pheophytin |
US7498342B2 (en) * | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
WO2006009797A1 (en) * | 2004-06-17 | 2006-01-26 | Plexxikon, Inc. | Azaindoles modulating c-kit activity and uses therefor |
JP4794832B2 (en) * | 2004-07-02 | 2011-10-19 | キヤノン株式会社 | Nucleic acid detection probe set and carrier |
US7867703B2 (en) * | 2004-08-26 | 2011-01-11 | Agilent Technologies, Inc. | Element defined sequence complexity reduction |
US7605168B2 (en) * | 2004-09-03 | 2009-10-20 | Plexxikon, Inc. | PDE4B inhibitors |
US20060073511A1 (en) | 2004-10-05 | 2006-04-06 | Affymetrix, Inc. | Methods for amplifying and analyzing nucleic acids |
US20060078889A1 (en) * | 2004-10-08 | 2006-04-13 | Arindam Bhattacharjee | Array-based methods for producing ribonucleic acids |
JP2008523786A (en) * | 2004-10-18 | 2008-07-10 | コドン デバイシズ インコーポレイテッド | Method for assembling high fidelity synthetic polynucleotides |
US20070122817A1 (en) * | 2005-02-28 | 2007-05-31 | George Church | Methods for assembly of high fidelity synthetic polynucleotides |
US20060102471A1 (en) | 2004-11-18 | 2006-05-18 | Karl Maurer | Electrode array device having an adsorbed porous reaction layer |
US7977119B2 (en) * | 2004-12-08 | 2011-07-12 | Agilent Technologies, Inc. | Chemical arrays and methods of using the same |
US8338093B2 (en) * | 2004-12-31 | 2012-12-25 | Affymetrix, Inc. | Primer array synthesis and validation |
US7547775B2 (en) * | 2004-12-31 | 2009-06-16 | Affymetrix, Inc. | Parallel preparation of high fidelity probes in an array format |
KR20070095452A (en) * | 2005-01-25 | 2007-09-28 | 스카이 제네틱스, 인코포레이티드 | Nucleic acids for apoptosis of cancer cells |
US20060183893A1 (en) * | 2005-01-25 | 2006-08-17 | North Don A | Nucleic acids for apoptosis of cancer cells |
DE602006018861D1 (en) * | 2005-01-27 | 2011-01-27 | Quest Diagnostics Invest Inc | FAST COMPARATIVE GENOM HYBRIDIZATION |
US7407757B2 (en) * | 2005-02-10 | 2008-08-05 | Population Genetics Technologies | Genetic analysis by sequence-specific sorting |
CA2614769A1 (en) | 2005-03-10 | 2006-09-21 | Verenium Corporation | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
US20060234264A1 (en) * | 2005-03-14 | 2006-10-19 | Affymetrix, Inc. | Multiplex polynucleotide synthesis |
BRPI0609140A2 (en) | 2005-03-15 | 2010-02-17 | Verenium Corp | cellulases, nucleic acids that encode them and methods for their production and use |
US20070034513A1 (en) | 2005-03-25 | 2007-02-15 | Combimatrix Corporation | Electrochemical deblocking solution for electrochemical oligomer synthesis on an electrode array |
US20090264635A1 (en) | 2005-03-25 | 2009-10-22 | Applera Corporation | Methods and compositions for depleting abundant rna transcripts |
US9394167B2 (en) | 2005-04-15 | 2016-07-19 | Customarray, Inc. | Neutralization and containment of redox species produced by circumferential electrodes |
US7452671B2 (en) * | 2005-04-29 | 2008-11-18 | Affymetrix, Inc. | Methods for genotyping with selective adaptor ligation |
AU2006272951A1 (en) | 2005-05-17 | 2007-02-01 | Plexxikon, Inc. | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
US20060281113A1 (en) * | 2005-05-18 | 2006-12-14 | George Church | Accessible polynucleotide libraries and methods of use thereof |
EP1910824A4 (en) | 2005-05-31 | 2012-11-21 | Labnow Inc | Methods and compositions related to determination and use of white blood cell counts |
SG162795A1 (en) * | 2005-06-15 | 2010-07-29 | Callida Genomics Inc | Single molecule arrays for genetic and chemical analysis |
DK1893612T3 (en) * | 2005-06-22 | 2011-11-21 | Plexxikon Inc | Pyrrole [2,3-B] pyridine derivatives as protein kinase inhibitors |
EP2508867A1 (en) * | 2005-06-24 | 2012-10-10 | Board Of Regents, The University Of Texas System | Systems and methods including self-contained cartridges with detection systems and fluid delivery systems |
WO2007005666A2 (en) * | 2005-07-01 | 2007-01-11 | Board Of Regents, The University Of Texas System | System and method of analyte detection using differential receptors |
US20070065877A1 (en) | 2005-09-19 | 2007-03-22 | Combimatrix Corporation | Microarray having a base cleavable succinate linker |
EP1941058A4 (en) * | 2005-10-27 | 2010-01-20 | Rosetta Inpharmatics Llc | Nucleic acid amplification using non-random primers |
US20070099195A1 (en) * | 2005-11-02 | 2007-05-03 | Huang Xiaohua C | Methods and compositions for separating nucleic acids from a solid support |
JP2009518004A (en) * | 2005-11-18 | 2009-05-07 | ザ チルドレンズ マーシー ホスピタル | Reduction of Cot-1 DNA distortion in nucleic acid hybridization |
US8076074B2 (en) | 2005-11-29 | 2011-12-13 | Quest Diagnostics Investments Incorporated | Balanced translocation in comparative hybridization |
EP1957645B1 (en) | 2005-12-06 | 2010-11-17 | Ambion Inc. | Reverse transcription primers and methods of design |
US11306351B2 (en) | 2005-12-21 | 2022-04-19 | Affymetrix, Inc. | Methods for genotyping |
CA2658227A1 (en) | 2006-01-17 | 2007-07-26 | Health Research, Inc. | Heteroduplex tracking assay |
EP2216403A3 (en) | 2006-02-02 | 2010-11-24 | Verenium Corporation | Esterases and related nucleic acids and methods |
NZ595498A (en) | 2006-02-10 | 2013-05-31 | Verenium Corp | Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them |
ES2682284T3 (en) | 2006-02-14 | 2018-09-19 | Bp Corporation North America Inc. | Xylanases, nucleic acids that encode them and methods to make and use them |
JPWO2007097443A1 (en) * | 2006-02-20 | 2009-07-16 | 国立大学法人 北海道大学 | Method for determining DNA base sequence |
CA2645225A1 (en) | 2006-03-07 | 2007-09-13 | Verenium Corporation | Aldolases, nucleic acids encoding them and methods for making and using them |
EP2316962B1 (en) | 2006-03-07 | 2014-07-09 | Cargill, Incorporated | Aldolases, nucleic acids encoding them and methods for making and using them |
US20080045471A1 (en) * | 2006-03-27 | 2008-02-21 | North Don A | Nucleic Acids For Apoptosis Of Cancer Cells |
US20070232556A1 (en) * | 2006-03-31 | 2007-10-04 | Montine Thomas J | Methods and compositions for the treatment of neurological diseases and disorders |
US20080194414A1 (en) * | 2006-04-24 | 2008-08-14 | Albert Thomas J | Enrichment and sequence analysis of genomic regions |
US8383338B2 (en) | 2006-04-24 | 2013-02-26 | Roche Nimblegen, Inc. | Methods and systems for uniform enrichment of genomic regions |
US20080194413A1 (en) * | 2006-04-24 | 2008-08-14 | Albert Thomas J | Use of microarrays for genomic representation selection |
EP2444413A1 (en) | 2006-08-04 | 2012-04-25 | Verenium Corporation | Methods for oil or gas well drilling, washing and/or fracturing |
WO2008027558A2 (en) * | 2006-08-31 | 2008-03-06 | Codon Devices, Inc. | Iterative nucleic acid assembly using activation of vector-encoded traits |
EP2617819B1 (en) | 2006-09-21 | 2016-04-27 | BASF Enzymes LLC | Phytases, nucleic acids encoding them and methods for making and using them |
BRPI0716872A2 (en) | 2006-09-21 | 2015-06-16 | Verenium Corp | Phospholipases, nucleic acids encoding them and methods for their manufacture and use |
EP2076609A1 (en) | 2006-10-10 | 2009-07-08 | Illumina Inc. | Compositions and methods for representational selection of nucleic acids fro complex mixtures using hybridization |
US8618248B2 (en) | 2006-10-31 | 2013-12-31 | President And Fellows Of Harvard College | Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
EP2094701A2 (en) | 2006-12-21 | 2009-09-02 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2008079909A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
PL3101128T3 (en) | 2006-12-21 | 2019-09-30 | Basf Enzymes Llc | Amylases and glucoamylases, nucleic acids encoding them and methods for making and using them |
PE20081581A1 (en) * | 2006-12-21 | 2008-11-12 | Plexxikon Inc | PIRROLO [2,3-b] PYRIDINES COMPOUNDS AS KINASE MODULATORS |
NZ610301A (en) | 2007-01-30 | 2015-03-27 | Bp Corp North America Inc | Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them |
US8080372B2 (en) * | 2007-04-11 | 2011-12-20 | Canon Kabushiki Kaisha | Method for detecting nucleic acid in sample, method for designing probes, system for designing probes therefor |
WO2008131039A2 (en) * | 2007-04-16 | 2008-10-30 | Board Of Regents, The University Of Texas System | Cardibioindex/cardibioscore and utility of salivary proteome in cardiovascular diagnostics |
CN103555735B (en) | 2007-04-27 | 2016-03-09 | 加利福尼亚大学董事会 | Plant CO 2sensor, encode their nucleic acid and manufacture and their method of use |
US20080293589A1 (en) * | 2007-05-24 | 2008-11-27 | Affymetrix, Inc. | Multiplex locus specific amplification |
MX2010000617A (en) | 2007-07-17 | 2010-05-17 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor. |
EP2173909A1 (en) | 2007-07-26 | 2010-04-14 | Roche Diagnostics GmbH | Target preparation for parallel sequencing of complex genomes |
US7507539B2 (en) * | 2007-07-30 | 2009-03-24 | Quest Diagnostics Investments Incorporated | Substractive single label comparative hybridization |
US9388457B2 (en) | 2007-09-14 | 2016-07-12 | Affymetrix, Inc. | Locus specific amplification using array probes |
US8716190B2 (en) | 2007-09-14 | 2014-05-06 | Affymetrix, Inc. | Amplification and analysis of selected targets on solid supports |
CN110577945A (en) | 2007-10-03 | 2019-12-17 | 维莱尼姆公司 | xylanases, nucleic acids encoding them, and methods for making and using them |
EP2053132A1 (en) * | 2007-10-23 | 2009-04-29 | Roche Diagnostics GmbH | Enrichment and sequence analysis of geomic regions |
US9382585B2 (en) | 2007-10-30 | 2016-07-05 | Complete Genomics, Inc. | Apparatus for high throughput sequencing of nucleic acids |
DE102007056398A1 (en) * | 2007-11-23 | 2009-05-28 | Febit Holding Gmbh | Flexible extraction method for the preparation of sequence-specific molecule libraries |
CN104651381A (en) | 2008-01-03 | 2015-05-27 | 巴斯夫酶有限责任公司 | Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them |
US20100029498A1 (en) * | 2008-02-04 | 2010-02-04 | Andreas Gnirke | Selection of nucleic acids by solution hybridization to oligonucleotide baits |
US9074244B2 (en) | 2008-03-11 | 2015-07-07 | Affymetrix, Inc. | Array-based translocation and rearrangement assays |
US20090246788A1 (en) | 2008-04-01 | 2009-10-01 | Roche Nimblegen, Inc. | Methods and Assays for Capture of Nucleic Acids |
WO2009137369A1 (en) * | 2008-05-03 | 2009-11-12 | Tufts Medical Center, Inc. | Neonatal salivary genomics |
JP2009268665A (en) * | 2008-05-07 | 2009-11-19 | Canon Inc | Inhalation device |
US20110111417A1 (en) | 2008-05-14 | 2011-05-12 | Millennium Pharmaceuticals, Inc. | Methods and kits for monitoring the effects of immunomodulators on adaptive immunity |
US8153391B2 (en) | 2008-08-29 | 2012-04-10 | Bunge Oils, Inc. | Hydrolases, nucleic acids encoding them and methods for making and using them |
US8357503B2 (en) | 2008-08-29 | 2013-01-22 | Bunge Oils, Inc. | Hydrolases, nucleic acids encoding them and methods for making and using them |
US8198062B2 (en) | 2008-08-29 | 2012-06-12 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
ES2581774T3 (en) | 2008-08-29 | 2016-09-07 | Janssen Biotech, Inc. | Markers and methods of evaluation and treatment of ulcerative colitis and related disorders using a panel of 20 genes |
EP2352998A4 (en) | 2008-11-07 | 2011-09-21 | Centocor Ortho Biotech Inc | Markers and methods for assessing and treating lupus patients susceptible to photoprovocation |
DE102008061774A1 (en) | 2008-12-11 | 2010-06-17 | Febit Holding Gmbh | Indexing of nucleic acid populations |
DE102008061772A1 (en) | 2008-12-11 | 2010-06-17 | Febit Holding Gmbh | Method for studying nucleic acid populations |
US20100331204A1 (en) | 2009-02-13 | 2010-12-30 | Jeff Jeddeloh | Methods and systems for enrichment of target genomic sequences |
ES2661310T3 (en) * | 2009-03-09 | 2018-03-28 | Bioatla, Llc | Mirac proteins |
WO2010114928A2 (en) * | 2009-04-03 | 2010-10-07 | F.Hoffmann-La Roche Ag | Compositions and uses thereof |
WO2010127186A1 (en) | 2009-04-30 | 2010-11-04 | Prognosys Biosciences, Inc. | Nucleic acid constructs and methods of use |
MX355638B (en) | 2009-05-21 | 2018-03-26 | Verenium Corp | Phytases, nucleic acids encoding them and methods for making and using them. |
US20120122161A1 (en) | 2009-05-22 | 2012-05-17 | Esther Musgrave-Brown | Sorting Asymmetrically Tagged Nucleic Acids by Selective Primer Extension |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
US20110059453A1 (en) * | 2009-08-23 | 2011-03-10 | Affymetrix, Inc. | Poly(A) Tail Length Measurement by PCR |
CN102630250A (en) | 2009-09-25 | 2012-08-08 | 基因诊断测试公司 | Multiplex (+/-) stranded arrays and assays for detecting chromosomal abnormalities associated with cancer and other diseases |
UA111708C2 (en) | 2009-10-16 | 2016-06-10 | Бандж Ойлз, Інк. | METHOD OF OIL REFINING |
UA109884C2 (en) | 2009-10-16 | 2015-10-26 | A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD | |
WO2011048495A1 (en) | 2009-10-19 | 2011-04-28 | Stichting Het Nederlands Kanker Instituut | Predicting benefit of anti-cancer therapy via array comparative genomic hybridization |
WO2011048498A2 (en) | 2009-10-19 | 2011-04-28 | Stichting Het Nederlands Kanker Instituut | Differentiation between brca2-associated tumours and sporadic tumours via array comparative genomic hybridization |
US20120277112A1 (en) | 2009-10-19 | 2012-11-01 | Stichting Het Nederlands Kanker Instituut | Predicting response to anti-cancer therapy via array comparative genomic hybridization |
EP2494069B1 (en) | 2009-10-30 | 2013-10-02 | Roche Diagniostics GmbH | Method for detecting balanced chromosomal aberrations in a genome |
US10207240B2 (en) | 2009-11-03 | 2019-02-19 | Gen9, Inc. | Methods and microfluidic devices for the manipulation of droplets in high fidelity polynucleotide assembly |
WO2011055232A2 (en) | 2009-11-04 | 2011-05-12 | Population Genetics Technologies Ltd. | Base-by-base mutation screening |
NZ629615A (en) | 2009-11-06 | 2016-01-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
WO2011066185A1 (en) | 2009-11-25 | 2011-06-03 | Gen9, Inc. | Microfluidic devices and methods for gene synthesis |
US9217144B2 (en) | 2010-01-07 | 2015-12-22 | Gen9, Inc. | Assembly of high fidelity polynucleotides |
US9927434B2 (en) | 2010-01-20 | 2018-03-27 | Customarray, Inc. | Multiplex microarray of serially deposited biomolecules on a microarray |
US20130053253A1 (en) | 2010-02-22 | 2013-02-28 | Population Genetics Technologies Ltd | Region of Interest Extraction and Normalization Methods |
US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
US20190300945A1 (en) | 2010-04-05 | 2019-10-03 | Prognosys Biosciences, Inc. | Spatially Encoded Biological Assays |
JP5893607B2 (en) | 2010-04-05 | 2016-03-23 | プログノシス バイオサイエンシズ インコーポレイテッドPrognosys Biosciences,Inc. | Spatial-encoded biological assay |
US20140018251A1 (en) | 2010-09-20 | 2014-01-16 | Stichting Het Nederlands Kanker Instituut | Methods for Predicting Response to Anti-Cancer Therapy in Cancer Patients |
WO2012051055A2 (en) | 2010-10-06 | 2012-04-19 | Bp Corporation North America Inc. | Variant cbh i polypeptides |
WO2012064975A1 (en) | 2010-11-12 | 2012-05-18 | Gen9, Inc. | Protein arrays and methods of using and making the same |
EP3000883B8 (en) | 2010-11-12 | 2018-02-28 | Gen9, Inc. | Methods and devices for nucleic acids synthesis |
JP5941069B2 (en) | 2011-02-07 | 2016-06-29 | プレキシコン インコーポレーテッドPlexxikon Inc. | Compounds and methods for kinase regulation and indications therefor |
AR085279A1 (en) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | SOLID FORMS OF {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDE OF PROPANE ACID-1- SULFONIC |
GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
RU2631487C2 (en) | 2011-05-17 | 2017-09-22 | Плексксикон Инк. | Kinases modulation and indications for its use |
DK3594340T3 (en) | 2011-08-26 | 2021-09-20 | Gen9 Inc | COMPOSITIONS AND METHODS FOR COLLECTING WITH HIGH ACCURACY OF NUCLEIC ACIDS |
ES2776144T3 (en) | 2011-10-28 | 2020-07-29 | Millennium Pharm Inc | Biomarkers of response to NAE inhibitors |
CA2855368A1 (en) | 2011-11-11 | 2013-05-16 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
CN104039328B (en) | 2011-11-11 | 2018-10-09 | 米伦纽姆医药公司 | To the biomarker of the reaction of proteasome inhibitor |
US9150853B2 (en) | 2012-03-21 | 2015-10-06 | Gen9, Inc. | Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis |
EP3543350B1 (en) | 2012-04-24 | 2021-11-10 | Gen9, Inc. | Methods for sorting nucleic acids and multiplexed preparative in vitro cloning |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
IL236303B (en) | 2012-06-25 | 2022-07-01 | Gen9 Inc | Methods for nucleic acid assembly and high throughput sequencing |
CA2886783A1 (en) | 2012-10-01 | 2014-04-10 | Millennium Pharmaceuticals, Inc. | Biomarkers and methods to predict response to inhibitors and uses thereof |
US9267171B2 (en) | 2013-02-28 | 2016-02-23 | New York University | DNA photolithography with cinnamate crosslinkers |
WO2014210225A1 (en) | 2013-06-25 | 2014-12-31 | Prognosys Biosciences, Inc. | Methods and systems for determining spatial patterns of biological targets in a sample |
DK3030682T3 (en) | 2013-08-05 | 2020-09-14 | Twist Bioscience Corp | DE NOVO SYNTHESIZED GENE LIBRARIES |
ES2913205T3 (en) | 2014-05-13 | 2022-06-01 | Bioatla Inc | Conditionally active biological proteins |
AU2015308818B2 (en) | 2014-08-28 | 2021-02-25 | Bioatla Llc | Conditionally active chimeric antigen receptors for modified T-cells |
US11111288B2 (en) | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
JP2017532019A (en) | 2014-09-03 | 2017-11-02 | バイオアトラ、エルエルシー | Discovery and production of conditionally active biological proteins in the same eukaryotic cell production host |
US10669304B2 (en) | 2015-02-04 | 2020-06-02 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
CA3225013A1 (en) | 2015-02-24 | 2016-09-01 | Bioatla, Llc | Conditionally active proteins |
US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10774374B2 (en) | 2015-04-10 | 2020-09-15 | Spatial Transcriptomics AB and Illumina, Inc. | Spatially distinguished, multiplex nucleic acid analysis of biological specimens |
WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
US9422596B1 (en) * | 2015-04-27 | 2016-08-23 | Norgen Biotek Corp. | Methods and columns for nucleic acid purification |
US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2017049231A1 (en) | 2015-09-18 | 2017-03-23 | Twist Bioscience Corporation | Oligonucleic acid variant libraries and synthesis thereof |
US11512347B2 (en) | 2015-09-22 | 2022-11-29 | Twist Bioscience Corporation | Flexible substrates for nucleic acid synthesis |
CA3006867A1 (en) | 2015-12-01 | 2017-06-08 | Twist Bioscience Corporation | Functionalized surfaces and preparation thereof |
RU2018123825A (en) | 2015-12-07 | 2020-01-15 | Плексксикон Инк. | COMPOUNDS AND METHODS FOR MODULATION OF KINASES, AND INDICATIONS FOR THIS |
IL308504A (en) | 2016-05-13 | 2024-01-01 | Bioatla Llc | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
EP3500672A4 (en) | 2016-08-22 | 2020-05-20 | Twist Bioscience Corporation | De novo synthesized nucleic acid libraries |
US10417457B2 (en) | 2016-09-21 | 2019-09-17 | Twist Bioscience Corporation | Nucleic acid based data storage |
TW201815766A (en) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | Compounds and methods for IDO and TDO modulation, and indications therefor |
EP3554514A4 (en) | 2016-12-16 | 2020-08-05 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
WO2018136202A2 (en) | 2016-12-23 | 2018-07-26 | Plexxikon Inc. | Compounds and methods for cdk8 modulation and indications therefor |
EP3586255A4 (en) | 2017-02-22 | 2021-03-31 | Twist Bioscience Corporation | Nucleic acid based data storage |
WO2018170169A1 (en) | 2017-03-15 | 2018-09-20 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
AU2018284227A1 (en) | 2017-06-12 | 2020-01-30 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
KR20200047706A (en) | 2017-09-11 | 2020-05-07 | 트위스트 바이오사이언스 코포레이션 | GPCR binding protein and method for synthesis thereof |
SG11202003574TA (en) | 2017-10-20 | 2020-05-28 | Twist Bioscience Corp | Heated nanowells for polynucleotide synthesis |
WO2019109016A1 (en) | 2017-12-01 | 2019-06-06 | Millennium Pharmaceuticals, Inc. | Biomarkers and methods for treatment with nae inhibitors |
CA3088911A1 (en) | 2018-01-04 | 2019-07-11 | Twist Bioscience Corporation | Dna-based digital information storage |
WO2019222706A1 (en) | 2018-05-18 | 2019-11-21 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
US11519033B2 (en) | 2018-08-28 | 2022-12-06 | 10X Genomics, Inc. | Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample |
WO2020123316A2 (en) | 2018-12-10 | 2020-06-18 | 10X Genomics, Inc. | Methods for determining a location of a biological analyte in a biological sample |
US11649485B2 (en) | 2019-01-06 | 2023-05-16 | 10X Genomics, Inc. | Generating capture probes for spatial analysis |
US11926867B2 (en) | 2019-01-06 | 2024-03-12 | 10X Genomics, Inc. | Generating capture probes for spatial analysis |
US11492727B2 (en) | 2019-02-26 | 2022-11-08 | Twist Bioscience Corporation | Variant nucleic acid libraries for GLP1 receptor |
WO2020176680A1 (en) | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
CN114729342A (en) | 2019-06-21 | 2022-07-08 | 特韦斯特生物科学公司 | Barcode-based nucleic acid sequence assembly |
WO2021092433A2 (en) | 2019-11-08 | 2021-05-14 | 10X Genomics, Inc. | Enhancing specificity of analyte binding |
EP4055185A1 (en) | 2019-11-08 | 2022-09-14 | 10X Genomics, Inc. | Spatially-tagged analyte capture agents for analyte multiplexing |
FI3891300T3 (en) | 2019-12-23 | 2023-05-10 | 10X Genomics Inc | Methods for spatial analysis using rna-templated ligation |
US11732299B2 (en) | 2020-01-21 | 2023-08-22 | 10X Genomics, Inc. | Spatial assays with perturbed cells |
US11702693B2 (en) | 2020-01-21 | 2023-07-18 | 10X Genomics, Inc. | Methods for printing cells and generating arrays of barcoded cells |
US11821035B1 (en) | 2020-01-29 | 2023-11-21 | 10X Genomics, Inc. | Compositions and methods of making gene expression libraries |
US11898205B2 (en) | 2020-02-03 | 2024-02-13 | 10X Genomics, Inc. | Increasing capture efficiency of spatial assays |
US11732300B2 (en) | 2020-02-05 | 2023-08-22 | 10X Genomics, Inc. | Increasing efficiency of spatial analysis in a biological sample |
US11835462B2 (en) | 2020-02-11 | 2023-12-05 | 10X Genomics, Inc. | Methods and compositions for partitioning a biological sample |
US11891654B2 (en) | 2020-02-24 | 2024-02-06 | 10X Genomics, Inc. | Methods of making gene expression libraries |
US11926863B1 (en) | 2020-02-27 | 2024-03-12 | 10X Genomics, Inc. | Solid state single cell method for analyzing fixed biological cells |
US11768175B1 (en) | 2020-03-04 | 2023-09-26 | 10X Genomics, Inc. | Electrophoretic methods for spatial analysis |
EP4242325A3 (en) | 2020-04-22 | 2023-10-04 | 10X Genomics, Inc. | Methods for spatial analysis using targeted rna depletion |
EP4153776A1 (en) | 2020-05-22 | 2023-03-29 | 10X Genomics, Inc. | Spatial analysis to detect sequence variants |
EP4153775A1 (en) | 2020-05-22 | 2023-03-29 | 10X Genomics, Inc. | Simultaneous spatio-temporal measurement of gene expression and cellular activity |
WO2021242834A1 (en) | 2020-05-26 | 2021-12-02 | 10X Genomics, Inc. | Method for resetting an array |
AU2021283184A1 (en) | 2020-06-02 | 2023-01-05 | 10X Genomics, Inc. | Spatial transcriptomics for antigen-receptors |
EP4025692A2 (en) | 2020-06-02 | 2022-07-13 | 10X Genomics, Inc. | Nucleic acid library methods |
WO2021252499A1 (en) | 2020-06-08 | 2021-12-16 | 10X Genomics, Inc. | Methods of determining a surgical margin and methods of use thereof |
WO2021252591A1 (en) | 2020-06-10 | 2021-12-16 | 10X Genomics, Inc. | Methods for determining a location of an analyte in a biological sample |
AU2021294334A1 (en) | 2020-06-25 | 2023-02-02 | 10X Genomics, Inc. | Spatial analysis of DNA methylation |
US11761038B1 (en) | 2020-07-06 | 2023-09-19 | 10X Genomics, Inc. | Methods for identifying a location of an RNA in a biological sample |
US11926822B1 (en) | 2020-09-23 | 2024-03-12 | 10X Genomics, Inc. | Three-dimensional spatial analysis |
US11827935B1 (en) | 2020-11-19 | 2023-11-28 | 10X Genomics, Inc. | Methods for spatial analysis using rolling circle amplification and detection probes |
WO2022140028A1 (en) | 2020-12-21 | 2022-06-30 | 10X Genomics, Inc. | Methods, compositions, and systems for capturing probes and/or barcodes |
EP4301870A1 (en) | 2021-03-18 | 2024-01-10 | 10X Genomics, Inc. | Multiplex capture of gene and protein expression from a biological sample |
WO2023034489A1 (en) | 2021-09-01 | 2023-03-09 | 10X Genomics, Inc. | Methods, compositions, and kits for blocking a capture probe on a spatial array |
EP4218981A1 (en) * | 2022-02-01 | 2023-08-02 | W. L. Gore & Associates, Inc. | Affinity chromatography devices containing a fibrillated polymer membrane for the separation of mrna and viral vectors from an aqueous mixture |
EP4218980A1 (en) * | 2022-02-01 | 2023-08-02 | W.L. Gore & Associates Inc. | Affinity chromatography devices containing a heat treated fibrillated polymer membrane for the separation of mrna and viral vectors from an aqueous mixture |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5202231A (en) * | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
US5437976A (en) * | 1991-08-08 | 1995-08-01 | Arizona Board Of Regents, The University Of Arizona | Multi-domain DNA ligands bound to a solid matrix for protein and nucleic acid affinity chromatography and processing of solid-phase DNA |
US5527681A (en) * | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
US5547839A (en) * | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
US5650274A (en) * | 1993-06-25 | 1997-07-22 | Hitachi, Ltd. | DNA analyzing method |
US5795714A (en) * | 1992-11-06 | 1998-08-18 | Trustees Of Boston University | Method for replicating an array of nucleic acid probes |
US5800992A (en) * | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US6013440A (en) * | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
US6103463A (en) * | 1992-02-19 | 2000-08-15 | The Public Health Research Institute Of The City Of New York, Inc. | Method of sorting a mixture of nucleic acid strands on a binary array |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE88762T1 (en) * | 1986-08-11 | 1993-05-15 | Siska Diagnostics Inc | METHODS AND COMPOSITIONS FOR TESTING WITH NUCLEIC ACID PROBES. |
KR910009834B1 (en) * | 1986-09-09 | 1991-11-30 | 카르브 고교 가부시끼가이샤 | Combination roll |
GB8822228D0 (en) * | 1988-09-21 | 1988-10-26 | Southern E M | Support-bound oligonucleotides |
JPH02299598A (en) * | 1989-04-14 | 1990-12-11 | Ro Inst For Molecular Genetics & Geneteic Res | Determination by means of hybridization, together with oligonucleotide probe of all or part of extremely short sequence in sample of nucleic acid connecting with separate particle of microscopic size |
US6040138A (en) * | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
US5795716A (en) * | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
-
1997
- 1997-03-10 US US08/815,395 patent/US6013440A/en not_active Expired - Lifetime
-
1999
- 1999-10-28 US US09/429,521 patent/US6280950B1/en not_active Expired - Lifetime
-
2001
- 2001-07-20 US US09/910,223 patent/US6440677B2/en not_active Expired - Lifetime
-
2002
- 2002-08-14 US US10/219,006 patent/US6828104B2/en not_active Expired - Lifetime
-
2004
- 2004-11-08 US US10/984,127 patent/US20050118633A1/en not_active Abandoned
-
2006
- 2006-02-22 US US11/360,146 patent/US20060204991A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5202231A (en) * | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5527681A (en) * | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
US5547839A (en) * | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
US5800992A (en) * | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5437976A (en) * | 1991-08-08 | 1995-08-01 | Arizona Board Of Regents, The University Of Arizona | Multi-domain DNA ligands bound to a solid matrix for protein and nucleic acid affinity chromatography and processing of solid-phase DNA |
US6103463A (en) * | 1992-02-19 | 2000-08-15 | The Public Health Research Institute Of The City Of New York, Inc. | Method of sorting a mixture of nucleic acid strands on a binary array |
US5795714A (en) * | 1992-11-06 | 1998-08-18 | Trustees Of Boston University | Method for replicating an array of nucleic acid probes |
US5650274A (en) * | 1993-06-25 | 1997-07-22 | Hitachi, Ltd. | DNA analyzing method |
US6013440A (en) * | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
Also Published As
Publication number | Publication date |
---|---|
US6440677B2 (en) | 2002-08-27 |
US6013440A (en) | 2000-01-11 |
US20010053526A1 (en) | 2001-12-20 |
US20030013114A1 (en) | 2003-01-16 |
US6280950B1 (en) | 2001-08-28 |
US6828104B2 (en) | 2004-12-07 |
US20050118633A1 (en) | 2005-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6280950B1 (en) | Nucleic acid affinity columns | |
US20200370105A1 (en) | Methods for performing spatial profiling of biological molecules | |
EP1630237B1 (en) | Isolation of nucleic acid fragments by hybridisation to a solid support | |
KR19990022543A (en) | Oligonucleotide Tags for Classification and Identification | |
US20020012940A1 (en) | Expression monitoring by hybridization to high density oligonucleotide arrays | |
WO2003066802A9 (en) | Gene expression analysis using nicking agents | |
JP2007521833A (en) | Genetic analysis by sequence-specific classification | |
JPH09504864A (en) | Microfabricated flow-through porosity device to detect binding reactions separately | |
US20030096239A1 (en) | Probes and decoder oligonucleotides | |
AU2028300A (en) | Methods and apparatus for flow-through hybridization | |
US6942974B2 (en) | Selective elution of immobilized multiplexed primer extension products | |
JP2003530894A (en) | Methods for monitoring the expression of alternatively spliced genes | |
JP2005500051A (en) | Oligonucleotide probe selection based on ratio | |
US20050064432A1 (en) | Nucleic acid amplification and detection | |
WO2002016649A2 (en) | Probes and decoder oligonucleotides | |
EP1127161B1 (en) | Method for making complementary oligonucleotide tag sets | |
US20060147940A1 (en) | Combinatorial affinity selection | |
US20040110132A1 (en) | Method for concentrate nucleic acids | |
US7833714B1 (en) | Combinatorial affinity selection | |
WO2004087908A1 (en) | Method of regenerating microarray and reagent kit for regenerating microarray | |
EP1654386A2 (en) | Methods for analyzing transcripts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |